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Abstract 
 
Adenosine (Ado) is an endogenous nucleoside released from almost all cell types. It exerts 
neuroprotective and anti-inflammatory functions by acting through four receptor subtypes 
A1, A2A, A2B and A3 (ARs). These receptors differ in their affinity for Ado, in the type of G 
protein that they recruit and finally in the downstream signalling that are activated in target 
cells. The levels of Ado in the interstitial fluid are in the range of 20-200 nM, but many 
pathophysiological conditions such as asthma, neurodegenerative disorders, chronic 
inflammatory diseases and cancer are associated with changes in Ado levels. The primary 
aim of Ado is to reduce tissue injury and promote repair by different receptor-mediated 
mechanisms, including the increase of oxygen supply/demand ratio, anti-inflammatory 
effects and stimulation of angiogenesis. The investigation of ARs and their ligands is a 
rapidly growing field; there is extensive evidence for the involvement of ARs in the 
physiological regulation of several homeostatic processes and their implication in the 
ethiology of many diseases. The aim of this work was to analyse the expression of ARs 
and the signalling pathway, transcription factors and cytochines activated by them in 
different pathophysiological conditions linked to hypoxic and inflammatory conditions.  
At first, the role of ARs was studied in healthy and aneuploid pregnancies to understand 
reasons of spontaneous abortion (SA). It has been suggested that the causes of SA in 
aneuploidy are no different to those in euploidy, with the increased frequency in the former 
perhaps being ascribable to a genetically-determined imbalance in the mediators of 
placental perfusion and uterine contraction. So aneuploidy can be used as a model of this 
event. The ado transduction cascade appears to be disturbed in Trisomy 21 (TR21) through 
reduced expression of A2BAR and A1AR. These anomalies may be implicated in 
complications such as fetal growth restriction, malformation and/or SA, well known 
features of aneuploid pregnancies. Therefore A1AR and A2BAR could be potential 
biomarkers able to provide an early indication of SA risk and their stimulation may turn 
out to improve fetoplacental perfusion by increasing nitric oxide (NO) and vascular 
endothelial growth factor (VEGF). 
Next, the effects of ARs in glial cells under inflammatory conditions have been 
investigated. Glial cells, astrocytes and microglia, are important contributors to 
inflammatory immune responses and hypoxia-inducible factor 1 (HIF-1α) is the key 
transcription factor that is upregulated in response to hypoxia and inflammatory stimuli. 
Ado, through A1AR and A3AR activation, reduces lipopolysaccharide (LPS)-stimulated 
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HIF-1α mRNA expression and protein accumulation by inhibiting LPS-triggered p42/p44 
mitogen-activated protein kinase (p44/42 MAPK) and serine/threonine protein kinase 
(Akt) phosphorylation in normoxic and hypoxic conditions. This leads to an inhibition of 
genes involved in inflammation like Inducible Nitric Oxide Synthase (iNOS) and A2BARs, 
that are stimulated by LPS and further increased by LPS in concert with hypoxia, whilst 
does not affect angiogenesis and metabolic related genes, with the exception of glucose 
transporter 1 (GLUT1) and hexokinase 2 (HK2) that are stimulated by LPS in normoxia 
and reduced by A1AR and A3AR activation. These findings add a new molecular pathway 
activated by Ado in astrocytes to give a reduction of genes involved in inflammation and 
hypoxic injury that may cohexist in stroke, ischemia and other central nervous system 
(CNS) disorders. 
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Adenosine 
 
In 1929, Drury and Szent-Györgyi first reported the concept of Adenosine (Ado) acting as an 
extracellular signalling molecule (Drury and Szent-Gyorgyi, 1929). Ado is an endogenous 
nucleoside modulator released from almost all cell types (Gessi et al., 2011). Ado plays a 
central role as a structural element of nucleic acids and in the energy metabolism of all living 
organism. The physiological effects of Ado were first described in the cardiovascular system 
and gastrointestinal tract (Drury and Szent-Gyorgyi, 1929). It is composed of a molecule of 
adenine attached to a ribose sugar molecule (ribofuranose) via a β-N9-glycosidic bond (Fig. 
1). Ado accumulates in the extracellular space in response to metabolic stress and cell 
damage, and elevations in extracellular Ado are found in conditions of ischaemia, hypoxia, 
trauma asthma, neurodegenerative disorders, chronic inflammatory diseases and cancer 
(Linden, 2001; Fredholm et al., 2001; Gessi et al., 2011; 2013). The rapid release of Ado in 
response to tissue-disturbing stimuli has a dual role in modulating homeostasis. First, 
extracellular Ado represents a pre-eminent alarm molecule that reports tissue injury in an 
autocrine and paracrine manner to surrounding tissue. Second, extracellular Ado generates a 
range of tissue responses that can be generally viewed as organ protective thereby mediating 
homeostasis. Ado elicits its physiological responses by binding to and activating one or more 
of the four transmembrane Ado receptors (ARs), denoted A1, A2A, A2B and A3. A prominent 
body of evidence supports the notion that the ability of Ado, acting at its receptors, to control 
the immune and inflammatory systems plays a key role in the modulatory effects of Ado in 
both health and disease. There are many promising emerging therapeutic approaches that are 
focused on the modulation of Ado in the immune system (Hasko et al., 2008). Ado also has 
receptor-indipendent effects, because extracellular Ado can cross the cell membrane and have 
a role in less well-defined intracellular mechanisms, including the AMP-activated protein 
kinase (AMPK), adenosine kinase (AK) and S-adenosylhomocysteine hydrolase pathway 
(SAHase) (Antonioli et al., 2013). 
Normally, it is present in body fluids in concentrations 20–200 nM, but in response to stress 
elevated levels of Ado, up to 300 µM are produced and released (Fredholm, 2010; Burnstock, 
2008; Lopes et al., 2011).  
Ado can be generated intracellularly by hydrolysis of AMP or SAHase. The former is 
mediated by intracellular soluble 5′ nucleotidase (5′NT) and the rate of Ado formation is 
largely controlled by the level of adenosine monophosphate (AMP), which provides a direct 
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link to energy metabolism (Newby et al., 1985). Interestingly, Ado can be converted back to 
AMP via the action of AK and together 5′ NT and AK generate a potential futile cycle that 
ensures that there will always be a not insubstantial amount of intracellular Ado. The other 
way in which intracellular Ado is formed depend on the action of SAHase. S-Adenosyl-L-
homocysteine (SAH) levels are increased with increasing rates of S-adenosylmethionine- 
dependent transmethylation. Interestingly, the enzyme can also catalyze the reverse reaction, 
i.e., formation of SAH from Ado and homocysteine and this has been used to generate an 
estimate of intracellular Ado concentration of around 100 nMol/L under basal conditions 
(Deussen et al., 1988). Indeed, whenever there is an imbalance between the rate of Adenosine 
triphosphate (ATP) synthesis and ATP utilization AMP tends to rise and consequently Ado 
formation increases. This can occur under extreme physiological conditions such as heavy 
exercise, increases in nerve activity, or reduced ambient oxygen, e.g., at elevated locations. It 
will also occur pathologically, e.g., in ischemia, local trauma, or in the interior of a solid 
tumor (Fredholm, 2007; Sitkovsky, 2009). 
Cell membrane–embedded nucleoside trasportes, which include equilibrative nucleoside 
transporters (ENTs) and concentrative nucleoside transportes (CNTs), shunt extracellular Ado 
into the intracellular space, thereby terminating ARs signaling. ENTs, which carry 
nucleosides along their concentration gradient across cell membranes, include four subtypes: 
ENT1, ENT2, ENT3 e ENT4. CNTs, which include CNT1, CNT2 and CNT3, mediate the 
intracellular influx of nucleoside against their concentration gradient by using the sodium ion 
gradient, which occurs across the cell membrane, as a source of energy (Antonioli et al., 
2013). Two enzymes play a key role in catabolizing Ado: Ado deaminase (ADA) and AK and 
they are responsible for an extremely short half-life of Ado in circulation (Fredholm et al., 
2001; 2011; Eltzschig, 2009). AK is critically important in maintaining the physiological 
levels of Ado low, and also in maintaining depots of adenine nucleotides (Boison, 2006; 
Fredholm, 2007). However, some cells also possess concentrating transporters that drive Ado 
intracellularly by an ion gradient (Young et al., 2008). Extracellular Ado can be generated 
from extracellular degradation of adenine nucleotides via CD39 and ATP diphosphohydrolase 
(Deaglio and Robson, 2011) and CD73-5′nucleotidase (Colgan et al., 2006). In addition, some 
cells express ecto-enzymes that convert 2′, 3′,or 3′5′-cAMP to AMP for further conversion to 
Ado (Verrier et al., 2011). Although not all cells express these enzymes (Langer et al., 2008), 
they are present in most cellular microenvironments and provide a means for rapid 
degradation of extracellular nucleotides. Indeed, it appears that most cells can under some 
circumstances release nucleotides via exocytosis, specialized transporters or connexin or 
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pannexin hemichannels. There is also sometimes exocytotic release from vesicles that in 
addition store hormones or neurotransmitters (Lazarowsky, 2012), and perhaps even more 
interestingly the release of ATP can occur without the release of hormone when hormone 
storage granules transiently contact the cell membrane in a so called kiss-and-run encounter 
(MacDonald et al.,2006; Fredholm, 2013). 
 
 
 
 
 
 
 
 
 
G protein–coupled receptors (GPCRs) 
 
Ado is the endogenous ligand of four types of GPCRs, designated A1, A2A, A2B, and A3 
(Fredholm et al., 2011). 
GPCRs comprise the largest protein superfamily in mammalian genomes. They share a 
common seven-transmembrane (7TM) topology and mediate cellular responses to a variety of 
extracellular signals ranging from photons and small molecules to peptides and proteins 
(Lagerstrom and Schiolth, 2008). Diversity of the extracellular ligands is reflected in the 
structural diversity of more than 800 human GPCRs, which can be grouped into five major 
families and numerous subfamilies on the basis of their amino acid sequences. Subdivision on 
the basis of sequence homology allows the definition of rhodopsin (Class A), secretin (Class 
B), adhesion, glutamate (Class C) and Frizzled receptor families (Friedriksson et al., 2003). 
During the past few years, crystallography of GPCR has experienced exponential growth, 
resulting in the determination of the structures of 16 distinct receptors, 9 of them in 2012 
Figure 1: Chemical Structure of Adenosine 
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alone (Katrick et al., 2013). Signal transduction by GPCRs is fundamental for most 
physiological processes - from vision, smell, and taste to neurological, cardiovascular, 
endocrine, and reproductive functions - thus making the GPCR superfamily a major target for 
therapeutic intervention (Overington et al., 2006). Current drug discovery efforts aim both to 
improve therapies for more than 50 established GPCR targets and to expand the list of 
targeted GPCRs (Lappano and Maggiolini, 2011; Katrick et al., 2013).  
GPCRs share a common 7 TM α-helix architecture and couple to G-proteins (Lefkiowitz, 
2004). The TM α-helices are connected by alternating three extracellular (EL) and 
cytoplasmic (CL) loops (EL1–EL3 and CL1–CL3), with the N-terminus (NT) extracellular 
and the C-terminus (CT) intracellular, arranged in an anticlockwise fashion as viewed from 
the extracellular surface. Binding of a stimulus, the so-called ‘ﬁrst messenger’, to the 
extracellular or TM domains of a GPCR triggers conformational changes in the 7TM structure 
that are transmitted through the intracellular receptor domains to promote coupling between 
the receptor and its cognate heterotrimeric G-proteins. The receptor stimulates G-protein 
activation by catalysing the exchange of guanosine triphosphate (GTP) for guanosine 
diphosphate (GDP) on the Gα subunit and dissociation of the GTP-bound Gα subunit from the 
Gβγ subunit heterodimer. Once dissociated, free Gα-GTP and Gβγ subunits regulate the 
activity of enzymatic effectors, such as adenylate cyclases (AC), phospholipase C (PLC) 
isoforms and ion channels, to generate small molecules, the “second messengers”. The second 
messengers, in turn, control the activity of protein kinases that regulate key enzymes involved 
in intermediate metabolism. Hydrolysis of GTP to GDP within Gα and subsequent 
reassociation of Gα-GDP and Gβγ completes the G-protein cycle (Fig.2) (Oldham et al., 
2008; Ding et al., 2013) 
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Figure 2: GPCR activation cycle. 
 
 
 
ARs, like other class A GPCRs, have long been thought to exclusively occur in a monomeric 
state. Monomeric receptors are sufficient to induce signaling (Whorton et al., 2008). At least 
some studies suggest signaling via dimers occurs only at higher receptor densities (White et 
al., 2007). More recently, however, evidence is accumulating that ARs can form dimeric or, 
more generally speaking, multimeric or oligomeric structures. Through self-association, 
homo-oligomers (“homomers”) can be formed. Hetero-oligomerization leading to 
“heteromers” may be the consequence of the association between ARs and preferred partners, 
mostly other GPCRs, including other AR subtypes (Fredholm et al., 2011). 
 
Adenosine receptors (ARs)  
 
Extracellular purines (Ado, ATP, and ADP) and pyrimidines (uridine diphosphate (UDP) and 
uridine triphosphate (UTP) comprise a family of molecules that exert a variety of important 
physiological functions via the activation of cell-surface receptors termed purine receptors. 
Although the physiologic effects of Ado and ATP have been recognized for over 80 years, 
purinergic receptors were first described in 1976 and two subfamilies were identified: P1 or 
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ARs (selective for Ado), and P2 or nucleotide receptors (selective for ATP, ADP and UTP, 
which act as extracellular signaling molecules) (Mediero and Cronstein, 2013).  
Four members of the Ado/P1 receptor family have now been cloned and characterized from a 
variety of species: A1, A2A, A2B, and A3, and selective agonists and antagonists have been 
identified. All P1 receptors couple to G-proteins, and modulate AC activity in an inhibitory 
(A1, A3) or stimulatory (A2A, A2B) fashion, resulting in cyclic adenosine monophosphate 
(cAMP) changes (Fig.3). P2 receptors are divided into two families: P2X and P2Y, based on 
molecular structure, transduction mechanisms, and pharmacological properties (Burnstock et 
al., 2012). 
 
 
Figure 3: Ado synthesis and receptor activation in the cell. 
(Antonioli et al., Nature Reviews Cancer 13, 842–857;2013) 
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Each AR subtype has a different pattern of tissue expression and ligand binding properties. In 
cell-based systems, A1ARs have the highest affinity for Ado (Ki=10 nmol/L). The Ki values 
for Ado for A2AAR A2BAR, and A3AR are 200, 2000, and 10000 nmol/L, respectively, for the 
human receptors. A3ARs are also activated by the Ado metabolite inosine (Ki 2300 nmol/L) 
(Rivkees and Wendler, 2012). 
Many biological functions have been attributed to Ado signaling. For example, the heart rate-
slowing effects of intravenous Ado that is used for patient treatment of supraventricular 
tachycardia are mediated through the A1AR (Delacretaz, 2006). The A2AAR is expressed on 
inflammatory cells: pharmacologic studies provided critical evidence that the activation of 
A2AAR on neutrophils attenuates inflammatory responses (Gessi et al., 2000; Ohta and 
Sitkovsky, 2001). The A2BAR is involved in hypoxia-adaptive responses (Kong et al., 2006; 
Eltzschig et al., 2003; 2004), for example, during myocardial ischemia (Eckle et al., 2012), 
Acute Kidney Injury (AKI) (Grenz et al., 2012a, Bauerle et al., 2011) or intestinal 
inflammation (Grenz et al., 2012b, Frick et al., 2009) - such as that occurring during 
inflammatory bowel disease. A3AR has been suggested as a tumoral marker (Gessi et al., 
2004) and is involved in the inhibition of cancer growth (Fishman et al., 2004) 
 
A1 Adenosine Receptor 
 
The A1AR has been cloned from several animal species, including humans, and is known to 
bear a close structural similarity across the species (Ravelic and Burnstock, 1998). As for 
signal transduction, the A1AR is coupled to members of the Gi/Go family of G proteins, 
whereby it induces inhibition of AC activity (Van Calker et al., 1979). In addition, it is 
thought to activate PLCβ, which is known to increase inositol 1,4,5-triphosphate (IP3) and 
intracellular Ca
2+
. A1AR is coupled to pertussis-toxin-sensitive potassium channels as well as 
KATP channels, particularly in cardiac tissue and neurons. Moreover, it may inhibit Q, P and 
N-type Ca
2+
 channels and modulate extracellular signal-regulated protein kinases (ERKs) 
(Fredholm et al., 2001). Furthermore, a role for the β-arrestin1/ERK mitogen-activated 
protein kinase (MAPK) pathway in regulating A1AR desensitization and recovery has 
recently been reported (Jajoo et al., 2010). 
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A1AR and central nervous system (CNS) 
The A1AR is widely distributed throughout the CNS, featuring particularly high levels in the 
brain cortex, cerebellum and hippocampus, as well as the dorsal horn of the spinal cord. It is 
present in both pre- and post-synaptic terminals, and modulates the activity of the nervous 
system at a cellular level. At the presynaptic level it mediates inhibition of neurotransmitter 
release, while at the postsynaptic level it induces neuron hyperpolarization. Thus, activation 
of A1AR via Ado is responsible for sedative, anticonvulsant, anxiolytic and locomotor-
depressant effects. Moreover, endogenous Ado levels are sufficient to tonically activate 
inhibitory A1AR, and caffeine, perhaps the most commonly used drug in the world, mediates 
its excitatory effects by antagonising this inhibition. Ado also has a fundamental role to play 
in analgesia (Eltzschig et al., 2009); indeed, both spinal and systemic administration of Ado 
or its analogs produces anti-nociception by A1AR activation in a variety of animal models 
(Boison, 2007; Gong et al., 2010; Nascimento et al., 2010; Sowa et al., 2010). These 
antinociceptive effects may be mediated by the inhibition of intrinsic neurons by an increase 
in K
+
 conductance and presynaptic inhibition of sensory nerve terminals, which would 
theoretically hinder the release of substance P and glutamate. Likewise, attenuation by N-
methyl-D-aspartate (NMDA)-induced production of NO may also be involved. Furthermore, 
Ado has been shown to mediate opioid analgesia (Gan and Habib, 2007). In addition, it has 
recently been reported that allopurinol, a potent inhibitor of the enzyme xanthine oxidase used 
primarily in the treatment of hyperuricemia and gout, induces anti-nociception related to Ado 
accumulation, an effect that is completely prevented by A1AR blockade  (Schmidt et al., 
2009). Compounds that are able to enhance the activity of the A1AR mediated by the 
endogenous ligand within specific tissues may have potential therapeutic advantages over 
non-endogenous agonists, due to allosteric modulation of GPCRs. As allosteric enhancers act 
only on the agonist A1AR-G protein ternary complex, limiting their action to sites and times 
of Ado accumulation, the use of these drugs to increase the responsiveness of the A1AR to 
endogenous Ado at sites of its production is an appealing alternative to activation by 
exogenous agonists (Romagnoli et al., 2010), especially as the former approach minimizes 
side effects such as dyspnea, chest pain, atrioventricular blockage or bronchospasm.  
A1AR and the respiratory system 
A1ARs are responsible for many effects induced by Ado, not only in the CNS but also in 
peripheral tissues (Russo et al., 2006; Baraldi et al., 2008). In particular, this signaling 
nucleoside has been implicated in the regulation of asthma and chronic obstructive pulmonary 
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disease (COPD) (Russo et al., 2006); Ado levels are elevated in the asthmatic lungs to an 
extent that can be directly correlated with the degree of inflammatory insult (Brown et al., 
2008a). Unsurprisingly, therefore, A1AR expression is also increased in the epithelium and 
airway smooth muscle of human asthmatics (Brown et al., 2008b). Early evidence of A1AR is 
involvement in asthma was provided by studies on allergic rabbit models, where the Ado-
induced acute bronchoconstrictor response was attenuated by pretreatment with A1AR 
antagonists. Accordingly in human airway tissue and bronchial smooth muscle cells, 
activation of A1AR has been shown to produce effects that cause airway hyper-
responsiveness. In particular, activation of A1AR in human airway epithelial cells causes an 
increase in the expression of the Mucin 2 (MUC 2) gene, which is responsible for mucus 
hypersecretion. Moreover, activation of A1AR is known to produce pro-inflammatory effects 
on various types of human cells (Ponnoth et al., 2010). As a whole, these effects of A1AR in 
humans suggest A1AR as an important therapeutic target in human asthma (Ethier and 
Madison, 2006; Baraldi et al., 2008; Wilson, 2008). Indeed, the non-selective AR antagonists 
theophylline and doxofylline have been launched as bronchodilators for the treatment of 
various respiratory disorders (Press et al., 2007). Paradoxically, however, findings in ADA-
deficient mice suggest the occurrence of anti-inflammatory actions of Ado in the lung, 
mediated through chronic A1AR activation of macrophages (Sun et al., 2005). Likewise, it has 
been recently reported that A1AR inhibits transendothelial and transepithelial 
polymorphonuclear cell migration in a murine model of lipopolysaccharide (LPS)-induced 
lung injury, presumably by reducing the release of chemotactic cytokines into the alveolar 
space. In addition, A1AR is involved in decreasing microvascular permeability and leukocyte 
transmigration in endothelial cells (Ngamsri et al., 2010), suggesting also a protective and 
anti-inflammatory role for A1AR (Gazoni et al., 2010).  
A1AR and the cardiovascular system 
At a cardiovascular level, A1ARs mediate negative chronotropic, dromotropic and inotropic 
effects. A1AR subtypes located on sinoatrial and atrioventricular nodes can cause bradycardia 
and heart block, respectively, while their negative inotropic effects include a decrease in atrial 
contractility and action potential duration. Recently, it has been shown that the selective 
deletion of the A1AR abolishes the heart-rate slowing effects of intravascular Ado in vivo 
(Koeppen et al., 2009). Stimulation of A1AR in the heart, on the other hand, exerts a 
cardioprotective effects by inhibiting norepinephrine release from sympathetic nerve endings 
(Schutte et al., 2006). Ado also protects tissues through ischemic preconditioning (IPC), a 
brief period of ischemia and reperfusion that can protect the myocardium against infarction 
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from a subsequent prolonged ischemic insult. This response, which has been most widely 
investigated in the heart, but also occurs in other tissues (Schneyvays et al., 2005; Grenz et 
al., 2007), is brought about by the activation of A1AR, protein kinase C (PKC) and 
mitochondrial KATP channels (Kiesman et al., 2009; Solenkova et al., 2006). A1AR agonists, 
for example, tecadenoson (N6-[3(R)- tetrahydrofuranyl]adenosine), are in development for 
arrhythmias and atrial fibrillation; clinical studies with intravenous tecadenoson suggest that it 
may slow the speed of atrio ventricular nodal conduction by selectively stimulating the A1AR, 
and may prevent blood pressure dropping by failing to stimulate the A2AAR (Yldiz et al., 
2007). In the kidney, on the other hand, A1AR mediates vasoconstriction, decrease in 
glomerular filtration rate and the inhibition of both renin secretion and neurotransmitter 
release. Thus, A1AR antagonists represent a novel class of agents for potential use in the 
treatment of hypertension and edema (Vallon et al., 2006). In fact, A1AR antagonists are more 
effective diuretics and natriuretics than thiazides, with the added advantage of reducing the 
potassium wastage and reductions of renal blood flow and glomerular filtration rate seen with 
the latter drugs (Zhou and Kost, 2006). Furthermore, evidence from genetically altered mice 
indicates that transcellular NaCl transport induces the generation of Ado, which, in 
conjunction with angiotensin II, elicits afferent arteriolar constriction through A1AR 
activation (Sun et al., 2001; Schnermann and Briggs, 2008). Moreover, clinical trials, albeit in 
a limited number of subjects, have demonstrated that A1AR antagonists produce natriuretic 
and hypotensive effects in hypertensive patients and attenuated the furosemide-induced 
decline of renal hemodynamic function in heart failure patients. Hence, selective A1AR 
antagonists targeting renal microcirculation are currently under development for the treatment 
of both chronic and acute heart failure. One of these novel pharmacological agents, rolofylline 
(1,3-dipropyl-8-(2-nor-1-adamantyl) xanthine, KW-3902), facilitates diuresis and preserves 
renal function through A1AR antagonism in patients with acute decompensated heart failure 
and renal dysfunction; pilot data also suggest beneficial effects on symptoms and short-term 
outcomes (Slawsky and Givertz, 2009). Nevertheless, despite several studies showing 
improvement of renal function and/or increased diuresis with A1AR antagonists, particularly 
in chronic heart failure, these findings were not confirmed in the large Phase III trials 
PROTECT 1 and 2 (Placebo-controlled Randomized study of the selective A1 antagonist 
Rolofylline for patients hospitalized with acute heart failure and volume Overload to assess 
Treatment Effect on Congestion and renal funcTion) in acute heart failure patients. In fact, the 
pooled/meta-analysis of two studies demonstrated that treatment with rolofylline was 
associated with poor outcomes due to worsening renal function in patients with acute 
decompensated heart failure (Watherley et al., 2010; Voors et al., 2011). Nonetheless, lessons 
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can be learned from these and other studies, and there is still hope for a clinical role for A1AR 
antagonists (Hocher et al., 2010; 2011).  
A1AR and inflammation 
Indeed, several studies have demonstrated that A1AR activation has a protective function in 
vivo, inhibiting necrosis, inflammation and apoptosis. Moreover, A1AR has been implicated 
as potent anti-inflammatory mediator in various kidney, heart, liver, lung and brain injury 
models (Gazoni et al., 2010; Pang et al., 2011). In particular A1AR activation appears to 
protect against hepatic injury by upregulation and phosphorylation of heat shock protein 27, a 
member of a family of chaperone proteins that serves to defend against cell damage (Chen et 
al., 2009). A critical role for Ado in bone homeostasis via interaction with A1AR has also 
been recently reported. In particular, due to the stimulatory effect played by A1AR on 
osteoclast function and formation, antagonists of this receptor may be able to prevent the bone 
loss associated with inflammatory diseases and menopause (Kara et al., 2010a; 2010b). 
Activation of A1AR inhibits lipolysis and lowers plasma concentrations of free fatty acids by 
inhibiting AC and downstream cAMP formation. Unfortunately, however, the majority of full 
A1AR agonists are plagued by significant cardiovascular effects. Hence, selective partial 
A1AR agonists have been developed (Dhalla et al., 2007a; 2007b). One such compound, 
CVT-3619 (2-{6-[((1R,2R)-2-hydroxycyclopentyl) amino] purin-9-yl(4S,5S,2R,3R)-5-[(2-
fluorophenylthio)- methyl]oxolane- 3,4-diol), is a partial A1AR agonist that has anti-lipolytic 
effects at concentrations that do not provoke cardiovascular symptoms (Fatholahi et al., 2006; 
Shearer et al., 2009).  A further advantage of these partial agonists is that they are 
accompanied by a minimal risk of ARs desensitization in response to chronic drug exposure 
(Vallon et al., 2006; Shearer et al., 2009). The A1AR receptor ligand candidates for novel 
therapeutic treatments currently undergoing clinical studies are listed in Table 1. 
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Table 1: Progress of A1AR ligands as novel therapeutic treatments (Gessi et al., Expert Opin. Investig. Drugs:20;1591-
1609; 2011) 
 
 
A2A Adenosine Receptor 
 
Of the four ARs, A2AARs have taken center stage as the primary anti-inflammatory effectors 
of extracellular Ado (Hasko and Pacher, 2008). The gene for the A2AAR has been cloned from 
several species including dog, rat, human, guineapig and mouse, and has demonstrated a high 
degree of homology among human, mouse and rat (Baraldi et al., 2008). The A2AAR 
stimulates AC activity through its coupling with Gs proteins; this leads to the activation of 
cAMP-dependent protein kinase A (PKA), which in turn phosphorylates and activates various 
receptors, ion channels, phosphodiesterases and phosphoproteins such as cAMP response 
element-binding protein (CREB) and dopamine- and cAMP-regulated neuronal 
phosphoprotein (DARPP-32). PKC triggering by A2AAR activation has also been reported. In 
the brain striatum, the A2A subtype stimulates Golf, another member of the Gs subfamily of G 
proteins. In addition, A2AAR can interact with different types of Ca
2+
 channels to either 
increase intracellular Ca
2+ 
or decrease Ca
2+
 influx and, like the other Ado subtypes, it is 
involved in the modulation of ERK activity. Due to a long carboxy-terminal domain, the 
A2AAR possesses a greater molecular mass (45 kDa) in comparison with the other subtypes 
(36-37 kDa). The A2AAR C-terminus has been defined as a crowded place where various 
accessory proteins, such as D2-dopamine receptors, α-actinin, ADP-ribosylation factor 
nucleotide site opener, ubiquitin-specific protease 4 and translin-associated protein X, may 
interact. In fact, it is thought that the lack or the presence of such varied partners may explain 
the conflicting effects resulting from A2AAR activation, for example, neuroprotection versus 
neurotoxicity (Sun et al., 2006). Recently, it has been demonstrated that agonist-bound 
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A2AAR structures possess common GPCR activation features (Lebon et al., 2011). GPCRs 
have similar structures, consisting of 7TM helices containing well-conserved sequence motifs, 
indicating that they are activated by a common mechanism. Recently described structures of 
β-adrenoceptors highlight residues in TM region 5 (H5) that initially bind specifically to 
agonists rather than to antagonists, suggesting that these residues play an important role in 
agonist-induced activation of receptors. In this context, important information concerning the 
different interactions occurring between agonists and antagonists with the A2AAR has recently 
come to light. In particular, agonists contain a ribose group that extends deep into the A2AAR 
ligand binding pocket, where it forms polar interactions with conserved residues in H7 and 
non-polar interactions with residues in H3. In contrast, an inverse agonist fails to interact with 
any of these residues; indeed, comparison with agonist bound structures indicates that these 
compounds sterically prevent conformational change in H5, thereby acting as inverse 
agonists. Furthermore, comparison of agonist-bound structures of A2AAR with agonist-bound 
structures of β-adrenoceptors has inferred that the contraction of the ligand-binding pocket 
caused by inward motion of helices 3, 5 and 7 may be a feature common to the activation of 
all GPCRs. It is evident that this detailed new structural information regarding these receptors 
has the potential to hugely influence rational drug design. 
A2AAR and the CNS 
A2AAR is found ubiquitously throughout the body, but its expression is particularly common 
in the immune system and the striato-pallidal system of the brain (Fredholm et al., 2001). 
A2AAR localization in basal ganglia is restricted to the GABA-contained neurons of the 
indirect pathway projecting from the caudate putamen to the globus pallidus, which also 
selectively expresses the D2 dopamine receptor and the peptide encephalin (Jenner et al., 
2009). This explains why several studies have investigated the possible involvement of 
A2AAR in the pathogenesis of neuronal disorders, including Huntington’s chorea and 
Parkinson’s disease (Varani et al., 2007; 2010;  Simola et al., 2008; LeWitt et al., 2008; 
Ramlackhansing et al., 2011). In fact, changes in A2AAR expression and signaling have been 
reported in various experimental models of Huntington’s disease, and an aberrant 
amplification of A2A-stimulated AC response has been demonstrated in striatal-derived cells 
engineered to express mutant Huntingtin protein. Moreover, a subsequent study also 
demonstrated an abnormal increase of A2AAR density in the peripheral blood cells of 
Huntington’s patients, as compared with age-matched healthy subjects (Varani et al., 2007). 
This suggests that the aberrant A2AAR phenotype may represent a novel biomarker of 
Huntington’s disease, which would be extremely useful in monitoring disease progression and 
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assessing the efficacy of novel neuroprotective approaches, not to mention providing grounds 
for further scientific investigation. Comparison of striatal A2AAR binding and AC activity in 
one of the best-characterized animal models of Huntington’s disease, R6/2 mice, in this case 
of different developmental ages, showed a transient increase in A2AAR density and A2AAR-
dependent cAMP production at early presymptomatic ages with respect to age-matched wild-
type animals (Varani et al., 2007). A2AAR in the CNS is also been implicated in the 
modulation of motor functions. Hence, A2AAR  antagonists are a useful alternative to 
dopaminergic drugs in the treatment of Parkinson’s disease (Simola et al., 2008). 
Accordingly, the A2AAR antagonist istradefylline (8-[2(E)-(3,4-Dimethoxyphenyl)vinyl]-1,3-
diethyl- 7-methylxanthine; KW-6002) has now been pre-registered as a Parkinson’s disease 
treatment in North America by Kyowa Hakko Kirin (LeWitt et al., 2008). Indeed, it has been 
extensively demonstrated that A2AAR antagonists have the potential to reverse motor deficits 
and enhance dopaminergic treatments in animal models of Parkinson’s disease. Furthermore, 
istradefylline, for example, in combination therapy with levodopa or dopamine agonists, has 
been shown to improve the symptoms of the disease in a Parkinsonian monkey model without 
either increasing the incidence or severity of dopaminergic related side effects or triggering or 
aggravating dyskinesia. In particular, an upregulation of A2AAR has been reported in 
Parkinson’s patients with levodopa-induced dyskinesias (LIDs), suggesting that A2AAR 
antagonists could be used, in combination with a reduction in the dosage of levodopa, to 
manage LIDs (Ramlackhansingh et al., 2011). The presence of an A2AAR alteration in the 
postmortem putamen of Parkinson’s disease patients as compared to healthy controls has also 
been demonstrated, confirming that A2AAR plays a key role in this neurological pathology. 
Furthermore, a selective increase of A2AAR density in the peripheral circulating cells of 
patients affected by Parkinson’s disease has been observed. As a whole, these data show that 
A2AAR alteration is a property common to both peripheral circulating cells and the putamen 
fraction in Parkinson’s disease, confirming that lymphocytes or neutrophils could represent a 
mirror of the CNS (Varani et al., 2010). In addition, A2AAR antagonists have been shown to 
attenuate neurotoxicity induced by kainite and quinolinate (Baraldi et al., 2008). 
A2AAR and the cardiovascular system  
Ado has also been shown to confer important protective effects on the cardiovascular system. 
Regadenoson (2-[4-(Nmethylcarbamoyl)- 1H-pyrazol-4-yl]Ado), a short-acting, selective 
A2AAR agonist, has already been approved as an adjunctive pharmacological stress agent for 
myocardial perfusion imaging studies, and was accordingly launched in the US in 2008 by 
Astellas Pharma. More recently, the safety and good tolerance of this drug, as well as the lack 
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of significant adverse cardiovascular events, has been demonstrated in post-heart transplant 
patients (Cavalcante et al., 2011). In addition, the results of a Phase III study, began in 
November 2009, to compare the safety and efficacy of Ado versus Apadenoson, another 
A2AAR agonist, in single-photon emission CT myocardial perfusion imaging in patients with 
coronary artery disease is eagerly awaited in September 2011 (ClinicalTrials.gov Identifier: 
NCT00990327) (Kern et al., 2006; Bayes, 2007).  
A2AAR, inflammation and the immune system 
Activation of the A2AAR subtype on a wide range of cells, namely platelets, coronary smooth 
muscle cells, endothelial cells, monocytes/macrophages and foam cells, has been shown to 
result in vasodilation, neo-angiogenesis, inhibition of proinflammatory cytokine production 
and the reduction of plaque formation (Belardinelli et al., 1998; Varani et al., 2000; Gessi et 
al., 2000; Blackburn et al., 2009; Bingham et al., 2010). Substantial lines of evidence have 
suggested that the majority of anti-inflammatory effects of endogenous Ado are mediated by 
A2AAR (Blackburn et al., 2009; Ohta and Sitkovsky, 2009). In particular, the dominant 
mechanism involved is likely to be the suppression of cytokine and chemokine expression by 
immune cells through A2AAR activation. In particular, Ado regulates the production of tumor 
necrosis factor (TNF-α) and macrophage inflammatory proteins (MIP)-1 α, MIP-1β, MIP-2 α 
and MIP-3 α, acting via neutrophil A2AAR (McColl et al., 2006). As previously mentioned, 
there is a particularly strong presence of A2AAR in the immune system. Studies on 
A2Aknockout (KO) models have shown that A2AAR activation inhibits interleukin (IL-2) 
secretion by naive CD4
+
 T cells, thereby reducing their proliferation, which confirms the 
immunosuppressive effects of A2AAR stimulation (Naganuma et al., 2006; Sevigny et al., 
2007). Indeed, one of the mechanisms by which immunosuppression is induced is T-
regulatory cell triggering of CD39 expression in order to generate Ado (Deaglio et al., 2007; 
Borsellino et al., 2007). Although A2AARs are generally viewed as negative regulators of 
immune cells, including activated T cells, it has recently been reported that A2AAR activation 
by Ado protects CD4
+
 T lymphocytes against activation-induced cell death. Because 
activation-induced cell death can be viewed as a process that terminates an immune response, 
the fact that it is prevented by A2AAR indicates that A2AAR activation can actually prolong 
immune processes, suggesting that the role of these receptors in regulating immune responses 
is more complex than previously thought. It is evident, then, that further studies aimed at 
determining the precise role of the antiapoptotic effect of A2AAR activation in the regulation 
of T-cell-mediated immune responses are required (Himer et al., 2010). It has also been 
demonstrated that A2AARs play an important role in the promotion of wound healing and 
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angiogenesis (Ahmad et al., 2009; Ernens et al., 2010). Moreover, A2AAR and A3AR are 
responsible for the anti-inflammatory actions of methotrexate (MTX) in the treatment of 
inflammatory arthritis (Montesinos et al., 2006; Chan and Cronstein, 2010). In rheumatoid 
arthritis patients, Ado has been reported to suppress the elevated levels of pro-inflammatory 
cytokines, including TNF-α and IL-1β. In a recent study, an upregulation of A2AAR  and 
A3AR receptors was found in lymphocytes and neutrophils obtained from early rheumatoid 
arthritis patients and MTX-treated patients. This alteration was associated with high levels of 
TNF-α and Nuclear Factor-KappaB (NF-kB) activation. Interestingly, the treatment with anti- 
TNF-α drugs normalized A2AAR and A3AR expression and functionality (Varani et al., 2009). 
These data consolidate the involvement of A2AAR and A3AR in rheumatoid arthritis and 
support the importance of these receptors in human diseases characterized by a marked 
inflammatory component. Activation of the A2AAR during reperfusion of various tissues has 
been found to markedly reduce ischemia-reperfusion injury. In particular, in a model of 
ischemia-reperfusion injury in the lung, that is, A2AAR stimulation with the selective agonist 
trans-4-[3-[6-amino-9-[(2R,3R,4S,5S)-5-(N-ethylcarbamoyl)- 3,4-dihydroxytetrahydrofuran-
2-yl]-9H-purin- 2-yl]-2-propynyl]cyclohexanecarboxylic acid methyl ester (apadenoson) is 
associated with decreased inflammation and greatly protects mouse lung from injury, when 
administered at the time of reperfusion (Gazoni et al., 2010). It has been widely reported that 
hypoxia-induced accumulation of Ado may represent one of the most fundamental and 
immediate tissue-protection mechanisms, with A2AAR triggering signals in activated immune 
cells. In these regulatory mechanisms, oxygen deprivation and extracellular Ado 
accumulation serve as “reporters”, while A2AAR serve as “sensors” of excessive tissue 
damage (Sitkovsky et al., 2004). The hypoxia-adenosinergic tissue-protecting mechanism is 
provoked by inflammatory damage to blood vessels, interruption in oxygen supply, low 
oxygen tension (i.e., hypoxia) and by the hypoxia-driven accumulation of extracellular Ado 
acting via immunosuppressive, cAMP-elevating A2AARs (Sitkovsky, 2009).  
A2AAR and the digestive system 
Another area where A2AAR signaling has received attention as a potential therapeutic target is 
the gastrointestinal tract; studies have highlighted the protective effects of A2AAR activation 
in various animal models of colitis, and these protective effects can be ascribed to two major 
mechanisms: decreased inflammatory-cell infiltration and increased activity of regulatory T 
cells (Nagamuna et al., 2006; Hasko and Pacher, 2008). A2AAR stimulation was found, in 
rats, to attenuate gastric mucosal inflammation induced by indomethacin. This effect was 
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obtained by blocking secondary injury caused by stomach inflammation, through a reduction 
of myeloperoxidase and pro-inflammatory cytokines (Koizumi et al., 2009). 
A2AAR and the respiratory system 
Increased Ado levels have been found in the lungs of individuals with asthma or COPD, and 
ARs are known to be expressed on most, if not all, inflammatory and stromal cell types 
involved in the pathogenesis of these diseases (Polosa and Blackburn, 2009). In addition, 
pharmacological treatment of allergic rats with an A2AAR agonist has been shown to result in 
diminished pulmonary inflammation. Moreover, a recent study in an ADA deficient model 
has demonstrated that genetic removal of A2AAR leads to enhanced pulmonary inflammation, 
mucus production and alveolar airway destruction (Mohsenin et al., 2007). Furthermore, 
A2AAR induced on Invariant Natural killer T (iNKT) and NK cells can reduce pulmonary 
inflammation in mice with sickle-cell anemia, improving baseline pulmonary function and 
preventing hypoxia-reoxygenation-induced exacerbation of pulmonary injury (Wallace and 
Linden, 2010). These findings further confirm the involvement of A2AAR in the anti-
inflammatory networks of the lung. In addition, a study performed in peripheral lung 
parenchyma has demonstrated that ARs affinity and/or density are altered in patients with 
COPD, as compared to smokers with normal lung function. Moreover, a significant 
correlation was found between the density and affinity of ARs and the forced expiratory 
volume in 1s:forced vital capacity ratio, a widely used index of airflow obstruction. In 
particular, A2AARs, as well as A3ARs, were found to be upregulated in COPD patients 
(Varani et al., 2006). This alteration may represent a compensatory response mechanism and 
could contribute to the anti-inflammatory effects mediated by stimulation of these receptors. 
Given the central role of inflammation in asthma and COPD, substantial preclinical research 
activity with the aim of understanding the function of A2AAR in models of airway 
inflammation is underway. A list of A2AAR ligands currently undergoing clinical trials as 
novel therapeutic treatments is reported in Table 2. 
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Table 2: Progress of A2AAR ligands as novel therapeutic treatments (Gessi et al., Expert Opin. Investig. 
Drugs:20;1591-1609; 2011). 
 
 
A2B Adenosine Receptor 
 
A2BARs have been cloned from the rat hypothalamus, human hippocampus and mouse mast 
cells. The tissue distribution of A2BAR was initially reported in peripheral organs such as the 
bowel, bladder, lung and vas deferens. As for the brain, mRNA and protein have been 
detected in hippocampal neurons and glial cells, but not in microglial cells (Colgan et al., 
2006). Following initial studies indicating selective induction of A2BAR by hypoxia, analysis 
of the cloned human A2BAR promoter identified within it a functional hypoxia-responsive 
region, including a functional binding site for hypoxia inducible factor 1 (HIF-1) (Kong et al., 
2006, Yang et al., 2010).The same study demonstrated transcriptional coordination of A2BAR 
by HIF-1α, and amplified Ado signaling during hypoxia, suggesting an important link 
between hypoxia and metabolic conditions related to inflammation and angiogenesis (Cohen 
et al., 2010). A2BAR have long been known to couple to AC activation through Gs proteins. 
However, an association between A2BAR and other intracellular signaling pathways, 
including Ca
2+
 mobilization through Gq proteins and MAPK activation, has been 
demonstrated (Colgan et al., 2006). A2BAR-induced stimulation of PLC results in 
mobilization of intracellular calcium and promotion of IL-8 production in human mast cells 
(HMC)-1 cells (Feoktikov and Biaggioni, 1995). Stimulation of A2BAR mediates the release 
of IL-6 from astrocytes. Due to the neuroprotective effect of IL-6 against hypoxia and 
glutamate neurotoxicity, activation of A2BAR subtype provides a damage-control mechanism 
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during CNS injury (Hasko et al., 2005). Functional studies have identified A2BAR in airway 
smooth muscle, fibroblasts, glial cells, gastrointestinal tract, vasculature and platelets. 
A2BAR and the cardiovascular system 
Vascular A2BAR may be associated with vasodilatation in both smooth muscle and the 
endothelium; this subtype plays a particularly important role in the modulation of 
vasodilatation in certain vessels such as the mesenteric, pulmonary and coronary arteries, but 
not in others where the A2AAR effect predominates (Feng and Navar, 2010). In 
juxtamedullary afferent arterioles, both A2AAR and A2BAR are functionally expressed, and 
via the latter, the powerful vasodilatory action of Ado is exerted, counteracting A1AR-
mediated vasoconstriction (Wakeno et al., 2006). Furthermore, in mIMCD-K2 cells, a murine 
model system for the renal inner medullary collecting duct, Ado stimulates Cl
-
 secretion 
through the cystic fibrosis transmembrane conductance regulator by activating apical A2BAR 
and signaling through cAMP/PKA. This suggests that the A2BAR pathway may provide one 
mechanism for enhancing urine NaCl excretion in the setting of high dietary NaCl intake 
(Rajagopal et al., 2010; Philipp et al., 2006). Activation of A2BAR may also prevent cardiac 
remodeling after myocardial infarction (Kuno et al., 2007). Protection from infarction has 
been also attributed to A2BAR in ischemic post-conditioning, through a pathway involving 
PKCε and Phosphoinositide 3-kinase (PI3K) (Kuno et al., 2008; Methner et al., 2010; Koda et 
al., 2010; Yang et al., 2010a). Furthermore, A2BAR/A3AR are known to mediate the 
cardioprotective effects induced by ischemic pre-conditioning through PKCε, aldehyde 
dehydrogenase type-2 (ALDH2) activation and renin inhibition (Koda et al., 2010). Finally, a 
new role for the A2BAR has been discovered in the regulation of platelet function. In 
particular, upregulated A2BAR have been found to modulate ADP receptor expression and 
inhibit agonist-induced aggregation in platelets under stress in vivo (Yang et al., 2010b). 
A2BAR and the digestive system 
According to mRNA analysis, which has revealed large amounts of A2BAR in the cecum and 
large intestine, A2BAR trigger an increase in cAMP levels in intestinal epithelial cells, which 
in turn provokes Cl
-
 secretion. This pathway results in the movement of isotonic fluid into the 
lumen, a process that naturally serves to hydrate the mucosal surface but, in extreme cases, 
produces secretory diarrhea (Strohmeier et al., 1995). Moreover, it has recently been reported 
that Ado increases HCO3
-
 secretion in intact epithelium in vivo through the activation of 
A2BARs expressed in the brush border membrane of duodenal villi (Ham et al., 2010). A2BAR 
stimulation of intestinal epithelial cells, by increasing intracellular cAMP levels, also leads to 
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IL-6 transcription via activation of the Activating transcription factors (ATF) and CREB and 
CCAAT/enhancer-binding protein beta (C/EBPb) (NF-IL-6) transcription factor systems. The 
physiological relevance of this response lies in the fact that it provides an amplification 
mechanism for intestinal inflammation, as neutrophils transmigrating through the epithelial 
cell layer release Ado, which in turn induces the production of the neutrophil-activating IL-6. 
This amplification loop is further enhanced by the rapid increase in the surface expression of 
A2BAR that occurs after stimulation of these cells with Ado, a phenomenon made possible by 
the prompt recruitment of preformed A2BAR from intracellular stores (Sitaraman et al., 2001). 
Furthermore, epithelial A2B mRNA and protein have been found to be upregulated via TNF-α 
in colitis, through a posttranscriptional mechanism involving microRNA (Kolachala et al., 
2010). Accordingly, A2BAR gene deletion has been found to attenuate murine colitis in mice 
(Kolachala et al., 2008). Conversely, however, recent studies combining pharmacological and 
genetic approaches have demonstrated that Ado signaling via the A2BAR dampens mucosal 
inflammation and tissue injury during experimental colitis or intestinal ischemia (Frick et al., 
2009). It has also been reported that A2BAR play a central regulatory role in IL-10 modulation 
during the acute inflammatory phase of dextran sodium sulfate colitis, thereby implicating the 
A2BAR expressed on intestinal epithelial cells as an endogenously protective protein 
(Eltzschig et al., 2009). The reason for these conflicting results is not clearly understood, 
although possible explanations may include inter-study disparity in colitis protocol, A2BAR-
deleted murine strains or animal housing conditions, the last leading to, for example, 
differences in the bacterial flora of the mice. Hence, additional comparison of the individual 
mouse strains tested is necessary if some of these apparent discrepancies are to be rectified. 
A2BAR and the respiratory system 
Recently, A2BARs have been implicated in the mediation of several pro-inflammatory effects 
of Ado in inflammatory cells of the lung. A2BARs have been reported to mediate 
degranulation and activation of canine mastocytoma and HMCs, thereby potentially playing a 
role in allergic and inflammatory disorders (Polosa and Blackburn, 2009). Ado constricts the 
airways of asthmatic patients through the release of histamine and leukotrienes from 
sensitized mast cells (Hasko et al., 2009); although the receptor involved seems to be the A3R 
in rats, it is the A2BAR that is implicated in humans. Accordingly, A2BAR antagonists potently 
inhibit the activation and degranulation of HMCs induced by Ado (Sun et al., 2006). In 
addition to mast cells, functional A2BARs have been found in bronchial smooth muscle cells 
and lung fibroblasts. In these cells, Ado, through stimulation of the A2B subtype, increases the 
release of various inflammatory cytokines, lending weight to evidence that A2BARs play a key 
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role in the inflammatory response associated with asthma. Furthermore, it has been reported 
that, through A2BAR activation, Ado-differentiated dendritic cells have impaired 
allostimulatory activity and express high levels of angiogenic, pro-inflammatory, immune 
suppressor and tolerogenic factors, including vascular endothelial growth factor (VEGF), IL-
8, IL-6, IL-10, cyclooxygenase (COX-2), Transforming growth factor beta (TGF-β) and 
indoleamine 2,3-dioxygenase (Ben Addi et al., 2008; Novitskiy et al., 2008). Moreover, using 
ADA KO animals, it has been shown that Dendritic Cells (DCs) with a pro-angiogenic 
phenotype are highly abundant in vivo under conditions associated with elevated levels of 
extracellular Ado. The first evidence for the involvement of A2BAR in asthma was provided 
by studies concerning the selectivity of enprofylline, a methylxanthine structurally related to 
theophylline (Feoktisov et al., 1998), and further support came from research demonstrating 
the presence of A2BAR on various type of cells involved in cytokine release in asthmatic 
disease, such as smooth muscle cells, lung fibroblasts, endothelial cells, bronchial epithelium 
and mast cells. Expression of A2BAR has also been found in the mast cells and macrophages 
of patients affected by COPD (Varani et al., 2006). In another study, activation of A2BAR in 
the HMC-1 mast cell line provoked an increase in IL-8 release in vitro (Feoktistov et al., 
1995). 
A2BAR and inflammation 
Recently, it has been reported that ADA-deficient mice treated with the selective A2BAR 
antagonist 3-ethyl-1-propyl- 8-[1-[3-(trifluoromethyl)benzyl]-1H-pyrazol-4-yl]xanthine 
(CVT-6883) showed reduced elevations in pro-inflammatory cytokines and chemokines as 
well as mediators of fibrosis and airway destruction (Yang et al., 2006). Interestingly, other 
authors have investigated the role of A2BAR in inflammation in vivo (Schingnitz et al., 2010). 
In particular, a study carried out on A2BAR KO mice, in which exon 1 of the A2BAR was 
replaced by a reporter gene, consented examination of endogenous A2BAR expression in 
various tissues and cell types. The results of this study show that there is abundant reporter 
expression in the vasculature and in macrophages. This new animal model emphasizes a role 
for the A2BAR not only in attenuating inflammation through the regulation of pro-
inflammatory cytokine production, but also in inhibiting leukocyte adhesion to the 
vasculature. Contrasting with the function of A2BAR in vasodilation, the A2BAR KO mice 
have normal blood pressure (Yang et al., 2006). This apparent contradiction between pro- and 
anti-inflammatory effects exerted by A2BARs may be related to differences between acute and 
chronic inflammation, that is, an A2BAR agonist may protect against acute endotoxin-
mediated lung toxicity while chronic accumulation of Ado could induce lung lesions. Studies 
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with a specific A2BAR agonist, 2-[6-amino-3,5- dicyano-4-[4-
(cyclopropylmethoxy)phenyl]pyridin-2-ylsulfanyl] acetamide (BAY 60-6583), have 
demonstrated attenuation of lung inflammation and pulmonary edema in wild type but not in 
A2BAR KO mice, thereby suggesting the A2BAR as a potential therapeutic target in the 
treatment of endotoxin-induced forms of acute lung injury (Schingnitz et al., 2010). 
Furthermore, the dependence of epithelial ciliary motility and pulmonary clearance on A2BAR 
activation has recently been reported (Allen-Gipson et al., 2011). 
A2BAR and cancer 
A2BARs play a role in cancer development by modulating both anti- and pro-tumoral effects. 
In particular, A2B receptor stimulation inhibits ERK1/2 phosphorylation in breast cancer cells, 
whilst it increases angiogenesis, proliferation, IL-8, VEGF and basic fibroblast growth factor 
in endothelial, foam and tumor cells (Gessi et al., 2010a). Recently, it has been reported that 
hypoxia-induced apoptosis of T cells is mediated by A2AAR and A2BAR, and that blocking the 
A2AAR signaling pathways can increase the anti-apoptotic function of T cells; this appears to 
suggest a new strategy for improving anti-tumor defences (Sun et al., 2010). A list of A2BAR 
ligands currently undergoing clinical trials as novel therapeutic treatments is reported in Table 
3.  
Table 3: Progress of A2BAR ligands as novel therapeutic treatments (Gessi et al., Expert Opin. Investig. 
Drugs:20;1591-1609; 2011). 
 
 
A3 Adenosine Receptor 
 
The A3AR is the only Ado subtype to be cloned before its pharmacological identification. It 
was originally isolated as an orphan receptor from rat testes that possessed 40% sequence 
homology with canine A1 and A2A subtypes. Homologues of the rat striatal A3AR have been 
cloned from sheep and humans showing, however, a large interspecies difference in A3 
structure, that is, the rat A3AR possesses only 74% sequence homology with sheep and 
humans (Baraldi et al., 2008; Baraldi and Borea, 2000). A3AR activation inhibits AC activity 
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by coupling with Gi proteins. In the rat mast cell line RBL-2H3 and rat brain, A3AR 
stimulation activates PLC through Gq proteins. Moreover, in some cells A3AR may also 
activate the MAPK signaling pathway, which is critical to the regulation of cell proliferation 
and differentiation (Raman et al., 2007). The A3AR is widely distributed and its mRNA is 
expressed in testis, lung, kidneys, placenta, heart, brain, spleen, liver, uterus, bladder, 
jejunum, proximal colon, eye of rat, sheep and humans (Jacobson, 1998; Gessi et al., 2008). 
A3AR and the CNS 
Interestingly, a dual role of A3AR has been reported in the brain. In particular, it seems that 
chronic pre-ischemic administration of the agonist 1-deoxy-1-[6-[[(3-iodophenyl)methyl] 
amino]-9H-purin-9-yl]-N-methyl-b-D-ribofuranuronamide (CF-101, IB-MECA) induces 
significant neuronal protection and reduction of the subsequent mortality, in contrast with the 
pronounced worsening of neuronal damage and post-ischemic mortality which accompanies 
acute administration of the drug. Furthermore, A3ARs also seem to play a role in a number of 
CNS functions, as revealed by mice featuring functional deletions of the A3AR, including 
nociception, locomotion, behavioral depression and neuroprotection. Consistent with previous 
reports of the neuroprotective actions of A3AR agonists, A3AR KO mice show an increase in 
neurodegeneration in response to repeated episodes of hypoxia, thereby suggesting that A3AR 
agonists may be useful in the treatment of ischemic and degenerative conditions of the CNS 
(Fedorova et al., 2003).  
A3AR and the cardiovascular system 
To date, several studies have provided evidence to support the theory that activation of A3AR 
is crucial for cardioprotection during and following ischemia-reperfusion, and it is likely that 
a considerable proportion of the Ado-mediated cardioprotective effects, once largely 
attributed to the A1AR, may now be in partly ascribable to A3AR activation (Ge et al., 2006). 
In fact, the cardioprotective effects of low levels of A3AR have been detected in transgenic 
mice, which showed no adverse effects, although higher levels of A3AR expression did lead 
to the development of dilated cardiomyopathy (Black et al., 2002). Similar data were 
observed in the case of A1AR overexpression (Funakoshi et al., 2006). The molecular 
mechanism of A3AR cardioprotection has been attributed to regulation of KATP channels. 
Moreover, as previously mentioned, a signaling cascade initiated by A2B/A3 subtypes that 
triggers PKC-mediated ALDH2 activation in cardiac mast cells contributes to IPC-induced 
cardioprotection by preventing mast cell renin release and the dysfunctional consequences of 
local renin angiotensin system (RAS) activation. Thus, unlike classic IPC, in which cardiac 
27 
 
myocytes are the main target, cardiac mast cells are the critical site for the development of the 
cardioprotective anti-RAS effects of IPC (Koda et al., 2010). A role of NO in A3AR -
mediated cardioprotection has been also reported. In particular, the involvement of inducible 
NO synthase (iNOS) as a downstream effector of the PI3K signaling cascade after activation 
of A3AR at reperfusion has been demonstrated (Karjian et al., 2006; 2008; Hussain et al., 
2009). Furthermore, A3AR stimulation restores vascular reactivity after hemorrhagic shock 
through a ryanodine receptor-mediated and calcium-activated potassium channel-dependent 
pathway (Zhou et al., 2010). Recently, it has been shown that Ado in hypoxic foam cells 
stimulates HIF-1α accumulation by activating all ARs. HIF-1α modulation appears to involve 
ERK1/2, p38 MAPK and Akt phosphorylation in the case of A1AR, A2AAR and A2BAR, while 
only ERK 1/2 activation is implicated in the case of A3AR. Furthermore, Ado, through the 
activation of A3AR and A2BAR, stimulates VEGF secretion in a HIF-1α-dependent way. 
Finally, Ado stimulates foam cell formation, and this effect is strongly reduced by A3AR and 
A2BAR blockers and by HIF-1α silencing. This study provides the first evidence that A3AR, 
A2BAR mixed A3/A2B antagonists may be useful in blocking important steps in Ado-induced 
atherosclerotic plaque development (Gessi et al., 2010a). 
A3AR and the respiratory system 
In addition to reducing injury in myocardial and vascular tissues, other beneficial anti-
inflammatory actions have been attributed to the A3 subtype, with particular relevance to the 
respiratory system. For example, A3ARs are expressed in human neutrophils where, together 
with A2AAR, they are involved in the reduction of superoxide anion generation; they have 
also been implicated in the suppression of TNF-α release induced by endotoxin from human 
monocytes (Gessi et al., 2002). In neutrophils, however, A3ARs also play a role in 
chemotaxis, in conjunction with P2Y receptors (Chen et al., 2006, Linden, 2006). Moreover, 
A3AR activation seems to inhibit degranulation and superoxide anion production in human 
eosinophils. Indeed, transcript levels for the A3 subtype are elevated in the lungs of asthma 
and COPD patients, where expression is localized to eosinophilic infiltrates. Similar evidence 
has also been observed in the lungs of ADA KO mice exhibiting Ado-mediated lung disease. 
Treatment of ADA KO mice with 3-propyl-6-ethyl- 5-[(ethylthio)carbonyl]-2 phenyl-4-
propyl-3-pyridine carboxylate (MRS 1523), a selective A3AR antagonist, prevented airway 
eosinophilia and mucus production (Young et al., 2004). Nevertheless, these findings contrast 
sharply with the results of experiments performed in human eosinophils ex vivo, where 
chemotaxis was reduced by A3AR activation, suggesting that significant differences exist 
between the impact of A3AR signaling on eosinophil migration ex vivo and in the whole 
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animal (Ezeamuzie and Philips, 1999). More recently, the involvement of the A3AR in a 
bleomycin model of pulmonary inflammation and fibrosis has been explored. Results 
demonstrated that A3AR KO mice exhibit enhanced pulmonary inflammation that involves an 
increase in eosinophils. Accordingly, a selective upregulation of eosinophil-related 
chemokines and cytokines was seen in the lungs of A3AR KO mice exposed to bleomycin, 
thereby suggesting that the A3AR performs anti-inflammatory functions in the bleomycin 
model (Morschl et al., 2008). Nonetheless, the role of the A3AR in the human lung, and 
indeed in asthma, still remains to be clarified. In general, receptor knockouts have provided 
significant new insights into Ado’s control of complex physiological (e.g., cognition) and 
pathological (e.g., neuroinflammation) phenomena, suggesting that further studies in these 
animal models would help in obtaining a clearer picture of the role of A3AR in inflammatory 
lung disease. What is clear, however, is that the expression of the A3AR in asthmatic airways 
is predominantly located in eosinophils (Brown et al., 2008a; Gessi et al., 2008; Wilson et al., 
2008).  
A3AR and cancer 
A3AR ligands appear to have found very interesting applications in cancer therapies, and the 
possibility that A3AR plays a role in the development of cancer has aroused considerable 
interest in recent years (Merighi et al., 2003; Gessi et al., 2011). The A3 subtype has been 
implicated in regulation of the cell cycle, and both pro- and antiapoptotic effects have been 
reported, depending on the level of receptor activation (Jacobson, 1998; Merighi et al., 2005a; 
Kim et al., 2010; Gessi et al., 2007; Taliani et al., 2010; Varani et al., 2011). Furthermore, the 
involvement of A3AR activation in inhibition of tumor growth has been demonstrated both in 
vitro and in vivo, leading to clinical trials being developed to test the efficacy of A3AR 
agonists in cancer treatment. The molecular mechanisms involved in the anticancer effects 
induced by A3AR agonists include regulation of the WNT pathway (Fishman et al., 2004), 
and it has been reported that Ado upregulates HIF-1α protein expression and VEGF protein 
accumulation by activating the A3 subtype in tumoral cells (Merighi et al., 2005b, 2006, 
2007a, 2007b). In contrast, A3AR blockade by etoposide and doxorubicin potentiates 
inhibition of VEGF secretion and affects HIF-1 expression in human melanoma cancer cells. 
This finding appears to infer the possibility of using AR antagonists to improve the ability of 
chemotherapeutic drugs to block angiogenesis (Merighi et al., 2009). The reason why both 
agonists and antagonists appear to be useful anticancer drugs in in vitro studies is not clear. It 
may be that the different ligands provoke the same response as a consequence of a 
desensitization process undergone by the receptor after agonist stimulation, or different 
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experimental conditions linked to oxygen concentrations may be implicated. Hence, A3AR 
antagonists should be tested on animal cancer models in order to shed light on this important 
issue. As regards studies on human tissues, overexpression of the A3 subtype has been 
demonstrated, as compared to normal mucosa, in colon cancer samples obtained from patients 
undergoing surgery. This overexpression was also reflected in peripheral blood cells, thereby 
rendering this Ado subtype a possible marker for cancer detection (Gessi et al., 2004a, 
2004b). Moreover, in a further study, it has been shown that A3AR mRNA expression is 
upregulated in hepatocellular carcinoma (HCC) tissues in comparison to adjacent normal 
tissues (Bar-Yehuda et al., 2008). Remarkably, upregulation of A3AR was also noted in 
Peripheral blood mononuclear cells (PBMCs) derived from these HCC patients with respect 
to levels in healthy subjects. These results provide further evidence that A3AR in PBMCs 
reflects receptor status in remote tumor tissue and may, therefore, represent a useful 
biomarker (Gessi et al., 2004b). The A3AR also reduces the ability of prostate cancer cells to 
migrate in vitro and metastasize in vivo. In particular, it has been reported that activation of 
the A3AR in these cells reduces PKA-mediated stimulation of ERK1/2, leading to lower 
levels of NADPH oxidase activity and cancer cell invasiveness (Jajoo et al., 2009). In a 
different study, the biological functions of Ado in Matrix Metallopeptidase 9 (MMP-9) 
regulation in U87MG human glioblastoma cells were investigated, revealing an increase of 
glioblastoma cell invasion (Gessi et al., 2010b). In this case, A3AR stimulation induced an 
increase of MMP-9 levels in U87MG cells by phosphorylation of ERK1/2, c-Jun N-terminal 
kinases (c-JNK)/stress-activated protein kinase, protein kinase B (PKB)/Akt and activator 
protein 1 (AP-1). A3AR is thus far the only AR to have been involved in “in vivo” cancer 
studies (Press et al., 2007), and the principal findings are summarized below. Studies 
performed to date include syngeneic, xenograft, orthotopic and metastatic experimental 
animal models utilizing IB-MECA and 2-chloro-N6-(3-iodobenzyl)Ado-5¢-
Nmethylcarboxamide (CF-102, Cl-IB-MECA) as the therapeutic agents in melanoma, colon, 
prostate and HCCs. In all experimental animal models, A3AR agonists were administered 
orally thanks to their stability and bioavailability profile. Oral administration of 10-100 μgkg-1 
IB-MECA and Cl-IB-MECA once or twice daily inhibited the growth of primary B16-F10 
murine melanoma tumors in syngeneic models. Moreover, in an artificial metastatic model, 
IB-MECA inhibited the development of B16-F10 murine melanoma lung metastases. The 
specificity of the response was demonstrated by the administration of an A3AR antagonist, 
which reversed the effect of the agonist. Furthermore, in combination with the 
chemotherapeutic agent cyclophosphamide, both IB-MECA and Cl-IB-MECA induced an 
additive antitumoral effect on the development of B16-F10 melanoma lung metastatic foci. 
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Oral administration of 10-100 μgkg-1 IB-MECA once or twice daily also inhibited the growth 
of primary CT-26 colon tumors. Furthermore, in xenograft models, IB-MECA inhibited the 
development of HCT-116 human colon carcinoma and PC3 human prostate carcinoma in 
nude mice. In these studies, the combined treatment of IB-MECA and 5-fluorouracil resulted 
in an enhanced antitumoral effect. Additionally, IB-MECA has also been shown to increase 
the cytotoxic index of taxol in PC3 prostate carcinoma-bearing mice and appears to be an 
efficacious inhibitor of liver metastases of CT-26 colon carcinoma cells inoculated in the 
spleen. Finally, Cl-IB-MECA treatment apparently inhibits hepatocellular tumor growth in a 
dose-dependent fashion (Bar-Yehuda et al., 2008; Fishman et al., 2009). 
A3AR and inflammation 
In addition, a role for A3AR in inflammation has been reported in literature. In arthritis, A3AR 
activation shows beneficial effects by suppression of TNF-α production (Fishman et al., 
2009). A3ARs suppress TNF-α release induced by endotoxin CD14 receptor signal 
transduction pathway from human monocytes and murine J774.1 macrophages. Moreover, in 
a macrophage model, the A3AR was the prominent subtype implicated in the inhibition of 
LPS-induced TNF-α production (Sajjadi et al., 1996). This effect was associated with changes 
in stimulation of the AP-1 transcription factor, whereas it was independent on MAPK, NF-kB, 
PKA, PKC and PLC. This was not confirmed in BV2 microglial cells where A3-mediated 
inhibition of LPS-induced TNF-α expression was associated with the inhibition of LPS-
induced activation of PI3K/Akt and NF-kB pathway (Lee et al., 2006a). The inhibitory effect 
induced by A3AR on TNF-α production was also assessed in A3KO mice, where the A3AR 
agonist was unable to reduce TNF-α levels in contrast with its effect in wild-type animals 
(Salvatore et al., 2000). Recently, it has been reported that in mouse RAW 264.7 cells the A3 
subtype inhibits LPS-stimulated TNF-α release by reducing calcium-dependent activation of 
NF-kB and ERK 1/2 (Martin et al., 2006). In contrast, in peritoneal macrophages, isolated 
from A3KO mice, the ability of IB-MECA to inhibit TNF-α release was not altered in 
comparison to wild-type mice (Kreckler et al., 2006). In this study, the inhibitory effect was 
exerted through the activation of A2AAR and A2BAR agonists as recently demonstrated also in 
human monocytes (Hasko et al., 2007). The discrepancy observed among these papers might 
not depend on species differences, being in both cases mouse cells, but by other factors 
including the source of the cells and/or the inflammatory stimulus used. However, in spite of 
these contrasting results, one of the best potential therapeutic applications of the regulatory 
role of A3AR activation on TNF-α release has been found in the treatment of arthritis. A3AR 
agonists exert significant antirheumatic effects in different autoimmune arthritis models by 
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suppression of TNF-α production. The molecular mechanism involved in the inhibitory effect 
of IB-MECA on adjuvant-induced arthritis included receptor downregulation and 
deregulation of the PI3K-NF-kB signaling pathway (Fishman et al., 2006; Madi et al., 2007). 
Previous studies also demonstrated that A3AR activation inhibited MIP-1α, which is a C-C 
chemokine with potent inflammatory effects, in a model of collagen induced arthritis, 
providing the first proof of concept of the utility of Ado agonists in the treatment of arthritis 
(Gessi et al., 2008). In agreement with an anti-inflammatory role for the A3AR, it has been 
recently demonstrated that A3AR activation decreases mortality and renal and hepatic injury 
in murine septic peritonitis (Lee et al., 2006b). Higher levels of endogenous TNF-α were 
observed in A3KO mice after sepsis induction, in comparison to wild-type animals and IB-
MECA significantly reduced mortality in mice lacking the A1AR or A2AAR but not the A3AR, 
demonstrating specificity of the A3AR agonist in activating A3 subtype and mediating 
protection against sepsis induced mortality (Lee et al., 2006b). Recently, in a mouse model of 
cecal ligation and puncture-induced sepsis, A3AR blockade reduces acute lung injury and 
polymorphonuclear leukocytes accumulation in lung tissue (Inoue et al., 2010). A similar 
mortality reduction associated with a decrease of IL-12 and Interferon (IFN-γ) production 
induced by A3AR activation was observed in endotoxemic mice. In addition, a reduced 
inflammation and increased survival following A3AR activation in two murine models of 
colitis has been reported. Furthermore, a protective role for A3AR in lung injury following in 
vivo reperfusion has been observed (Matot et al., 2006). This effect has been attributed to the 
stimulation of A1AR, A2AAR and A3AR leading to increased lung compliance and 
oxygenation, decreased pulmonary artery pressure, decreased neutrophil infiltration, 
decreased edema and reduced TNF-α production (Gazoni et al., 2010). ARs have been 
implicated in many ocular and systemic ischemic diseases (e.g., retinal ischemia). The A3 KO 
mouse showed lower intracellular pressure suggesting a role for A3AR antagonists in the 
therapy of glaucoma (Yang et al., 2005). Accordingly, nucleoside-derived antagonists to 
A3ARs lower mouse intraocular pressure and act across species (Wang et al., 2010). 
Furthermore, retinal ganglion cells express A3AR. Agonists for the A3AR prevented the Ca
2+
 
rise and cell death, which accompanied activation of the P2X7 and NMDA receptors 
suggesting a neuroprotective potential of A3AR agonists for glaucoma treatment. These 
findings have been confirmed in in vivo experiments (Zhang et al., 2006a; 2006b, 2010; Hu et 
al., 2010). Importantly, studies from Phase II clinical trial reveal that CF-101, given orally, 
was well tolerated and induced a statistically significant improvement in patients with 
moderate to severe dry eye syndrome. These data and the anti-inflammatory characteristic of 
CF-101 support further studies of the drug as a potential treatment for the signs and symptoms 
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of dry eye syndrome (Avni et al., 2010). A list of A3AR ligand candidates for novel 
therapeutic treatments currently in clinical studies is reported in Table 4. 
Table 4: Progress of A3AR ligands as novel therapeutic treatments (Gessi et al., Expert Opin. Investig. Drugs:20;1591-
1609; 2011). 
 
 
Conclusion 
In conclusion, a considerable amount of data from in vitro and in vivo experiments suggest 
that AR ligands regulate the course of numerous diseases and conditions (Tables 1,2,3,4), 
including pain, cancer, inflammation, neurological, cardiovascular and respiratory diseases, 
making ARs potential targets for therapeutic intervention in several pathological conditions.  
The investigation of ARs and their ligands is a rapidly growing field; there is now extensive 
evidence for the involvement of ARs in the physiological regulation of several homeostatic 
processes and their implication in the etiology of many diseases. It is understandable, 
therefore, that these compounds are having an increasing impact on the drug discovery and 
development process. Indeed, over the past 30 years, a considerable body of research has 
resulted in the identification of clinical candidates for AR agonism, partial agonism and 
antagonism (Figure 4).  
Furthermore, it is exciting to note that several molecules from the purine world have 
completed the long road of drug development. In particular, regadenoson is already 
commercially available, while binodenoson (2-[2 (cyclohexylmethyl)hydrazino]Adenosine) 
and istradefylline have now been pre-registered. Furthermore, other molecules such as 
tecadenoson, rolofylline, tonapofylline (3-[4-(1,3-dipropylxanthin-8-yl)bicyclo[2.2.2] oct-1-
yl]propionic acid) and CF-101 are at an advanced stage of clinical trials and, with luck, could 
soon become widely available. Despite this encouraging progress, however, many issues 
surrounding ARs still remain to be clarified. In fact, the opportunities for further research are 
almost boundless as all four ARs have been detected in association with a host of mammalian 
tissues and appear to control the pathogenesis of inflammatory and degenerative diseases in 
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many organ systems. This offers ripe opportunities for the development of AR 
agonists/antagonists for multiple indications, but also presents the challenge of making sure 
these compounds are devoid of side effects due to the action of AR subtypes on other organ 
systems. Fortunately, however, recent developments in the field of ARs agonists and 
antagonists have helped scientists to design and develop more specific and safer lead and 
back-up candidates for clinical development. Whereas the majority of these novel molecules 
are being considered as therapeutic agents for a range of pathological conditions, including 
Parkinson’s disease, neurological disorders, stroke, heart and renal failure, asthma and cancer, 
others are aimed at basic scientific applications, such as receptor probes and radioligands 
(Varani et al., 2000a; Gessi et al., 2005a). Indeed, based on the significant scientific and 
clinical advances summarized in this thesis, purine scientists do seem to be getting closer to 
their goal: the incorporation of Ado ligands into drugs with the ability to improve human 
health and even save lives. 
 
 
 
 
 
 
 
 
  
Figure 4: Bar graph showing the progress of ARs ligands in clinical development 
(Gessi et al., Expert Opin. Investig. Drugs:20;1591-1609; 2011). 
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Introduction 
 
15% of human pregnancies are known to end in spontaneous abortion (SA) before 12 weeks 
of gestation, and immunity, angiogenesis and apoptosis-related genes have all been 
implicated. In aneuploidy, however, the reported percentage of SA is much higher (Vesce et 
al., 2002). One possible reason could be that the chromosomal abnormality itself leads to 
miscarriage, but if this is the case, the pathogenic mechanism is still unknown. It has also 
been suggested that the causes of SA in aneuploidy are no different to those in euploidy, with 
the increased frequency in the former perhaps being ascribable to a genetically-determined 
imbalance in the mediators of placental perfusion and uterine contraction (Vesce et al., 2002). 
In this scenario, mediators such as VEGF and NO may be involved; indeed, a critical role has 
been reported for both in placental angiogenesis (Levine et al., 2004; Carmeliet et al., 1996). 
During gestation, angiogenesis occurs extensively in the placenta and villi to supply the fetus 
with oxygen and nutrition. This vascular development during embryonic and fetal growth in 
utero is triggered by hypoxia, a condition that is also known to increase the levels of Ado 
(Simon and Keith, 2008). This important hormone is locally released from metabolically 
active cells, or generated extracellularly by the degradation of ATP. Acting through its AR 
subtypes A1, A2A, A2B and A3, this nucleoside has been shown to regulate a wide variety of 
physiological processes, including angiogenesis in hypoxic tissues (Fredholm et al., 2011). In 
particular, Ado plays an important role in the regulation of VEGF from placental villi in 
hypoxic conditions, and it also increases NO be a major factor in maintaining normal 
fetoplacental function (Escudero and Sobrevia, 2008; George et al., 2010).  
 
Angiogenesis 
 
During normal pregnancy, dramatically increased feto- and utero-placental blood flows are 
highly correlated with fetal growth and survival as well as neonatal birth weights and 
survivability (Rosenfeld et al., 1974; Reynolds and Redmer, 1995; Reynolds et al., 2005). 
These increased blood flows are primarily caused by angiogenesis, vasodilatation, and 
vascular remodeling (Barcroft and Barron, 1946; Magness and Zheng, 1996; Osol and 
Mandala, 2009). Two potent angiogenic factors, fibroblast growth factor 2 (FGF2) and 
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VEGFA, are key factors regulating placental vascular growth, vasodilatation, and vascular 
remodeling (Klagsbrun and D’Amore, 1991; Ferrara et al., 2003; Osol and Mandala, 2009). 
Local endothelial production of vasodilators such as NO is increased during pregnancy in 
temporal association with increases in the production of placental angiogenic factors and may 
play an active role in the integral regulation of placental angiogenesis and vasodilatation 
(Myatt, 1992; Magness and Zheng, 1996; Sladek et al., 1997; Magness, 1998; Szukiewicz et 
al., 2005; Brownbill et al., 2007; Sprague et al., 2010). VEGFA is also a member of a family 
of structurally homologous growth factors with a potent angiogenic activity for vascular 
endothelial cells (Ferrara et al., 2003). Biological actions of VEGFA are initiated upon 
binding to its high affinity receptors including VEGFR1 (Flt1) and VEGFR2 (Gille et al., 
2000; Ferrara et al., 2003). VEGFR2 is the major signal transducer of VEGFA, responsible 
for mediating VEGFA-stimulated major steps of angiogenesis (endothelial cell proliferation 
and migration) and vasodilatation, whereas VEGFR1 may inhibit VEGFR2-mediated 
endothelial functions (Gille et al., 2000; Ferrara et al., 2003). However, knocking down either 
of these receptors in the mouse impairs vascular growth and development during the early 
embryonic stage, ultimately leading to embryonic death, indicating that both VEGFR1 and 
VEGFR2 are important for vascular formation and growth during early embryonic stage 
(Fong et al., 1995; Shalaby et al., 1995). Over the past two decades, it has become clear that 
apart from being a potent vasodilator (Dulak and Jozkowicz, 2003), NO is also a key mediator 
of angiogenesis (Bussolati et al., 2001; Hida et al., 2004). Expression of endothelial NO 
synthase (eNOS) and iNOs has been identified in the placenta of human, rhesus monkey, rat, 
and sheep (Conrad et al., 1993; Zarlingo et al., 1997). In association with robust fetoplacental 
angiogenesis (Reynolds and Redmer, 1995; Magness and Zheng, 1996), the NO level was 
increased in maternal circulation as pregnancy progresses in sheep (Vonnahme et al., 2005), 
and in late human pregnancy (Williams et al., 1997; Wang and Zheng, 2012). 
 
Adenosine and Angiogenesis in pregnancy 
 
The role of Ado in the placental vessels remains poorly investigated. Reid (Reid et al., 1990) 
reported that Ado has a biphasic response in the ovine fetal placental vasculature, an 
observation that may indicate the expression of a mixed ARs population along the placental 
vasculature or signaling mechanisms at variance. On the other hand, ATP contracts superficial 
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chorionic vessels from the human placenta (Huidobro and Valdecantos, 2000; Valdecantos et 
al., 2003). Considering that ATP is rapidly inactivated by releasable ectonucleotidases 
(Westfall et al., 2002), the possibility exists that even though the placenta lacks sympathetic 
perivascular nerves, the ATP released to the fetal-placental circulation will be rapidly 
degraded to Ado and modulate the ATP vasomotor response. The Ado-induced 
vasoconstriction of human chorionic vessels is mediated by the activation of A2BAR, an effect 
that appears to be related to the synthesis of an arachidonate metabolite that ultimately 
activates a thromboxane receptor in the vascular smooth muscles (Donoso et al., 2005). Ado 
stimulates endothelial cell proliferation and migration via activation of A2A and/or A2B ARs 
involving increased expression of angiogenic factors, including VEGF (Feoktistov et al., 
2004; Adair, 2005; Ryzhov et al., 2007; Fang and Olah, 2007). VEGF is the unique mitogen 
that acts specifically in endothelial cells by activating VEGFR (Olsson et al., 2006; Kerbel, 
2008). Activation of VEGFR triggers intracellular signalling pathways that involve increased 
NO synthesis (Roy et al., 2008; Casanello et al., 2007), a gas that seems to be determinant in 
endothelial cell proliferation in the fetal-placental unit (Escudero and Sobrevia, 2008). Ado 
could contribute up to 50-70% of the angiogenic response in some condition such as hypoxia 
(Adair, 2005) via a direct mitogenic effect on endothelium (Auchampach, 2007) or by 
regulating the production of pro-angiogenic substances, such as VEGF and IL-8 (Feoktistov 
et al., 2002; 2004; Clark et al., 2007) or anti-angiogenic factors such as thrombospondin 1 
(Desai et al., 2005) from endothelial and immune cells (Auchampach, 2007). Recently, it has 
been reported that 5'-N-ethylcarboxamidoadenosine (NECA) increased intracellular cAMP 
level due to activation of Gs proteins leading to ERK1/2 activation (i.e. phosphorylation) in 
human umbilical vein endothelial cells (HUVEC). NECA effect was associated with A2BAR 
activation rather than other receptors since the selective A2BAR antagonist MRS-1754 (N-(4-
cyano-phenyl)-2-[4- (2,6-dioxo-1,3-dipropyl-2,3,4,5,6,7-hexahydro-1H-purin-8- yl)-
phenoxy]acetamide) blocked NECA effect on ERK1/2 (Fang and Olah, 2007). Interestingly, a 
reduced A2BAR expression induced by the use of a ribozyme selectively designed, blocked 
NECA effect on human retinal endothelium migration and mouse endothelial proliferation 
(Afzal et al., 2003). Other studies show that NECA via A2BAR activation increases the VEGF 
gene promoter activity, as well as VEGF mRNA level and protein abundance in the cultured 
medium in human microvascular endothelial cell line 1 (HMEC-1) (Feoktistov et al., 2002). It 
has also been shown that expression and protein abundance of VEGF is increased in HUVEC 
cultured in its physiological oxygen content (i.e. ~5% O2) exposed to NECA (Feoktistov et 
al., 2004). More recently, using primary cultures of human monocytes it has been shown that 
A1AR activation by the selective agonist CPA (N6-cyclo-pentylAdenosine) increased the 
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VEGF level, an effect blocked with the selective antagonists WRC-0571 (N6-[endo-2'-(endo-
5'- hydroxy)norbornyl]-8-(N-methylisopro-pylamino)-9-methyladenine) and CPX (8-
cyclopentyl-1,3-dipropylxanthine) (Clark et al., 2007). In addition, interaction between Ado 
and VEGF had been also suggested in in vivo models where ado infusion (0.14 mg/kg/min, 6 
h) increased (3-fold) the VEGF plasma level in humans (Adair et al., 2005).Thus, Ado could 
activate ARs, probably A2A and/or A2B subtypes, increasing cAMP intracellular levels and 
ERK1/2 phosphorylation to induce VEGF expression and proliferation of human 
microvascular endothelium (Escudero et al., 2009). 
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Aim of the thesis 
 
Although ARs expression has been characterized in human placenta from normal pregnancies, 
no data are as yet available concerning expression and signaling cascades triggered by ARs in 
aneuploidies (Fox and Kurpis, 1983; Schocken and Schneider, 1986). Nevertheless, as 
previously mentioned, aneuploidies very often end in SA, making them a good experimental 
model for potentially shedding light on the mechanism regulating this event. The aim of this 
study was therefore to investigate the expression of ARs in first-trimester chorionic villi (CV) 
and isolated mesenchymal cells (MC) from both euploid (E) and Trisomy 21 (TR21) 
pregnancies, one of the most frequent autosomal aneuploidy; viable cells, namely those 
obtained via routine chorionic villus sampling, rather than SA tissue, were chosen, as any 
alteration of ARs in the latter could be a consequence rather than the cause of miscarriage. 
The rationale behind the study was that elucidating the role of Ado in the modulation of 
important proangiogenic molecules like VEGF and NO in aneuploid pregnancies may also 
shed light on the proteins and pathways involved in SA in E pregnancy. 
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Materials and Methods 
 
Materials 
[
3
H]1,3-dipropyl-8-cyclopentyl-xanthine ([
3
H]DPCPX) (specific activity 120 Ci/mmol), was 
purchased by NEN Research Products(Boston, MA). [
3
H] (4-(2-[7-amino-2-(2-furyl)-
[1,2,4]triazolo-[2,32][1,3,6]triazinyl-amino]ethyl)-phenol) ([
3
H]ZM 241385) (specific activity 
20 Ci/mmol), was furnished by Tocris (Boston, MA). [
3
H]N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-
dipropyl-2,6-dioxo-2,3,6,7-tetrahyro-1 H-purin-8-yl)-1-methyl-1 H-pyrazol-3-yl-oxy]-
acetamide] ([
3
H]MRE 2029-F20) (specific activity 123 Ci/mmol) and [
3
H]5-N-(4- 
methoxyphenylcarbamoyl)-amino-8-propyl-2-(2-furyl)-pyrazolo[4,3e] 
1,2,4triazolo[1,5c]pyrimidine ([
3
H]MRE 3008 F20) (specific activity 67 Ci/mmol), were 
synthesized at Amersham International (Buckinghamshire, UK). ARs small interfering RNA 
(siRNA) were from Santa Cruz DBA (Milano, Italy). RNAiFect Transfection Kit was 
purchased from Qiagen (Milano, Italy). Antibody against A1 and A3 ARs were obtained from 
Calbiochem Inalco (Milano, Italy). Antibody against A2A was from Alpha Diagnostic, Vinci 
Biochem (Firenze, Italy). Antibody against A2B was from Santa Cruz, Tebu-bio (Milano, 
Italy). VEGF ELISA kit was purchased from R&D Systems, Space Import–Export (Milano, 
Italy) and NO ELISA kit was furnished by Merck Chemicals (Nottingham, UK). CD45, 
CD34, CD14, CD73, CD90, CD13, CD31 antibodies were purchased from BD Biosciences 
(Milano, Italy), CD105 was from Space Import–export Milano (Milano, Italy). The Assays-
on-demand™ Gene expression Products Hs00181231_m1, Hs00169123_m1, 
Hs00386497_m1, Hs00181232_m1, Hs01573922_m1, Hs00173626_m1 for A1, A2A, A2B, A3, 
CD73 and VEGF, respectively were purchased from Applied Biosystems (Monza, Italy). 
Unless otherwise noted, all other reagents were purchased from Sigma (Milano, Italy). 
Study subjects and sample collection  
From 2008 to 2011 CV were collected from 71 pregnant women consecutively scheduled for 
sampling at 12 weeks of gestation. Pregnancies were categorized as follows: 41 E and 30 
TR21. Informed consent was obtained in all cases, and the study was approved by the Ferrara 
S. Anna University Hospital Ethics Committee. 
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Membrane preparation from CV 
Membrane preparation from 23 CV (13E and 10TR21) was carried out as described 
previously with minor modifications (Masnikosa et al., 2008). Briefly, tissue was 
homogenized in a polytron homogenizer with 50 mM 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) buffer (pH 7.5) containing 250 mM sucrose, 1 mM 
Ethylenediaminetetraacetic acid (EDTA) and 2 mM phenylmethyl-sulphonyl fluoride 
(PMFS). The homogenate was centrifuged at 600 ×g for 15 min. The pellet was discarded and 
the supernatant centrifuged at 18,000 ×g for 30 min. The supernatant obtained was further 
centrifuged at 100,000 ×g for 60 min. The crude membrane pellet was washed twice and 
finally resuspended in membrane buffer (50 mM HEPES, pH 7.5 containing 4 mM MgCl2). 
Binding studies 
Saturation experiments of [
3
H]DPCPX (0.1-30 nM), [
3
H]ZM 241385 (0.1–30 nM), [3H] MRE 
2029 F20 (0.1–30 nM) and [3H]MRE 3008 F20 (0.1–30 nM) to label A1, A2A, A2B and A3 
ARs, respectively, were carried out inmembranes from CV as previously described (Gessi et 
al., 2010). 100 μl of membrane homogenate (80 μg of protein assay−1) were incubated in 
duplicate, in a final volume of 250 μl in test tubes containing 50 mM Tris HCl buffer (10 mM 
MgCl2 for A2A, 10mM MgCl2 , 1mM EDTA, 0.1mM benzamidine for A2B and 10 mM MgCl2, 
1 mM EDTA for A3) pH 7.4, with 10–12 different concentrations of each selective 
radioligand. Non-specific binding was obtained by using 1-Butyl-8-(hexahydro-2,5-
methanopentalen-3a(1 H)-yl)-3,7-dihydro-3-(3-hydroxypropyl)-1H-purine-2,6-dione (PSB 
36), 2-(2-Furanyl)-7-[3-(4-methoxyphenyl)propyl]-7 Hpyrazolo[4,3-e][1,2,4]triazolo[1,5-
c]pyrimidin-5-amine (SCH 442416), 8-[4-[4-(4-Chlorophenzyl)piperazide-1-
sulfonyl)phenyl]]-1-propylxanthine (PSB 603) and N-(2-Methoxyphenyl)-N'-[2-(3-
pyrindinyl)-4-quinazolinyl]-urea (VUF 5574) 1 μM and at the KD value for each radioligand 
was 31, 30, 32, 26%, respectively of total binding in E and 39, 30, 41, 34%, respectively in 
TR21 cells. Bound and free radioactivity were separated, after an incubation time of  2h  at 4 
°C, by filtering the assay mixture through Whatman GF/B glass-fiber filters using a cell 
harvester (Packard Instrument Company). The filter bound radioactivity was counted on Top 
Count Microplate Scintillation Counter (efficiency 57%) with Micro-Scint 20. 
Western blot analysis 
AR expression was evaluated in CV samples (4E and 4TR21) and in mesenchymal cells (3E 
and 3TR21) by Western blot.Whole cell lysates, prepared as previously described were 
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resolved on a 10% SDS gel and transferred onto the nitrocellulose membrane (Gessi et al., 
2010). Aliquots of total protein sample (50 μg) were analyzed using antibodies specific for 
A1, A2A, A2B and A3 ARs (1:1000 dilution) in 5% non-fat dry milk in PBS 0.1% Tween-20 
overnight at 4–8°C. Membranes were washed and incubated for 1 hour at room temperature 
with peroxidase-conjugated species specific secondary antibodies. Specific reactions were 
revealed with the Enhanced Chemiluminescence Western blotting detection reagent. Tubulin 
(1:250) was used to mathematically normalize samples; then signals were expressed as % of 
control. 
Densitometry analysis 
The intensity of each band in immunoblot assay was quantified using a VersaDoc Imaging 
System (Bio-Rad). Mean densitometry data from independent experiments were normalized 
to the results in control cells. The data were presented as the mean±S.E. 
MC isolation 
MC cells were isolated from a total of 40 CVs (24E,16TR21) as previously described (Poloni 
et al., 2008). Only cells taken from back-up cultures were used after karyotype analysis. Cells 
were maintained in Chang medium D, supplemented with 20% fetal calf serum, 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, at 37° in 5% CO2/ 95% air. All 
cell treatments with ARs ligands were performed in the presence of ADA. 
Hypoxic treatment 
Hypoxic exposure (24 h) was performed in a modular incubator chamber flushed with a gas 
mixture containing 1%O2, 5%CO2 and balance N2 (MiniGalaxy, RSBiotech). 
Immunophenotyping 
MCs isolated from 3 separate CV samples were immunophenotyped. Analysis was performed 
using an EPICS-XL flowcytometer and EXPO32 software (Beckman Coulter). At least 
10,000 events were collected per sample (Mirandola et al., 2011). 
Real-time RT-PCR 
Quantitative real-time RT-PCRwas performed as previously reported (Gessi et al., 2010). 
Total cytoplasmic RNA was extracted from MCs (13E, 8TR21) by the acid guanidinium 
thiocyanate phenol method. For the real-time RT-PCR of A1, A2A, A2B, A3 ARs, CD73 and 
VEGF the assays-on- demand™ Gene expression Products were used. As reference gene the 
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endogenous control human β-actin kit was used, and the probe was fluorescent-labeled with 
VIC™ (Applied Biosystems, Monza, Italy). 
Immunofluorescence analysis 
For HIF-1α detection cells were treated with NECA for 2 h, under hypoxia. MCs (5E, 5TR21) 
were washed two times with PBS, fixed in 10% paraformaldehyde for 10 min, permeabilized 
in a PBS solution containing 0.1% of Triton X-100 and incubated for 30 min with PBS plus 
5% goat serum and 0.5% bovine serum albumin. The cells were then incubated O.N. at 4 °C 
in a humidified chamber with anti-HIF-1α Ab solutions (1:50) containing 0.5% of goat serum 
and 0.5% of bovine serum albumin in PBS. Excessive antibody was washed away with PBS 
and rabbit antibodies were detected with fluorescein isothiocyanate- labeled goat anti-rabbit 
IgG. Coverslips were stained with 4¢,6¢,-diamino- 2-phenyl-indole, mounted in DABCO 
glycerol-PBS and observed on Nikon fluorescent microscope (Eclipse 50i) as previously 
described (Merighi et al., 2012). Images were analyzed using NIS Elements BR 3.0 software 
(Nikon Instruments Inc., Milan, Italy). Levels of hypoxic HIF-1 in euploid cells were the 
basis for calculation of the additional NECA-mediated increase and for HIF-1 staining in 
aneuploid cells. The mean intensity of each cell was obtained from the cells pixels that had a 
higher intensity than that of the mean background intensity. A mean of 150 cells was analyzed 
for each condition at 40X magnification, at fixed time exposure. 
siRNA treatment of MCs 
MCswere plated in six-well plates and grown to 50–70% confluence before transfection.  
Transfection of ARs siRNA, was performed at a concentration of 100 nM using RNAiFectTM 
Transfection Kit for 72 hours (Gessi et al., 2010). A non-specific control ribonucleotide sense 
strand (5’-ACU CUA UCU GCA CGC UGA CdTdT-3’) and antisense strand (5’-dTdT UGA 
GAU AGA CGU GCG ACU G-3’) were used under identical conditions.  
Nitrite assay for mesenchymal cells 
NOS activity in MCs (5E, 5TR21) was assessed indirectly by measuring nitrite (NO2
-
) 
accumulation in the cell culture media using a colorimetric kit (Calbiochem, Milan, Italy). At 
the end of the treatment period, the nitrite concentration in the conditioned media was 
determined according to a modified Griess method (Merighi et al., 2012). Briefly, the NADH 
dependent enzyme nitrate reductase was used to convert the nitrate to nitrite prior to 
quantification of the absorbance, measured at 540 nm by a spectrophotometric microplate 
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reader (Fluoroskan Ascent, Labsystems, Sweden). Sodium nitrite was used as the standard 
compound.  
Enzyme-linked immunosorbent assay (ELISA) 
The levels of VEGF secreted by theMCs (5E, 5TR21) in the medium were determined by 
ELISA kits. In brief, subconfluent cells (40,000/ml) were seeded in 24-well plates 
andincubated in the presence of solvent or various concentrations of ado ligands for 24 hours. 
The medium was collected, centrifuged for 5 min at 900 g to remove floating cells and 
assayed for VEGF and NO content by ELISA according to the manufacturer's instructions. 
The data were presented as mean±SE from four independent experiments. 
Statistical analysis 
LIGAND, a weighted nonlinear least-squares curve-fitting program, was used for computer 
analysis of the data fromsaturation experiments (Gessi et al., 2010). Functional experiments 
were calculated by non-linear regression analysis using the equation for a sigmoid 
concentration-response curve (GraphPAD Prism, San Diego, CA, USA). Data sets were 
analyzed using Student's t test or analysis of variance (ANOVA) and Dunnett's test (when 
required). A P-value of less than 0.05 was considered statistically significant. All values in the 
figures and text are expressed as mean±standard error (S.E.) of independent experiments and 
are indicated in the figure legends. Each experiment was performed by using the CV derived 
from one single donors, and was performed in duplicate (for binding and real-time PCR 
experiments) or in triplicate (for functional experiments). The experiments were repeated at 
least three times as indicated from n-values that represent the number of patients used. 
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Results 
 
AR proteins in E and TR21 CV 
Immunoblotting was used to investigate AR expression in CV biopsies from E and TR21 
pregnancies. Expression of A1, A2B and A3ARs was lower in TR21 CV with respect to E CV, 
while no difference in A2AAR was observed between the two (Fig. 5A). The specificity of the 
A2B antibody, recognizing a band of 50 kDa different from the predicted molecular wheight of 
36 kDa, was assessed in both untransfected and transfected CHO cells as shown in 
supplemental Fig. 1. Saturation binding experiments in CV were carried out to evaluate 
affinity (KD) and density (Bmax) of ARs. [
3
H]DPCPX saturation assays revealed A1ARs with 
KD of 2.4±0.3 and 1.9±0.2 nM, and Bmax of 203±21 and 107±12 fmol/mg of protein in E and 
TR21 samples, respectively; [
3
H]ZM 241385 saturation studies showed A2AARs with KD of 
2.5±0.3 and 2.8±0.3 nM, and Bmax of 78±10 and 72±9 fmol/mg of protein in E and TR21 
samples, respectively; [
3
H]MRE2029F20 saturation experiments detected A2BARs with KD of 
2.8±0.3 and 3.2±0.3 nM, and Bmax of 140±15, and 90±12 fmol/mg of protein in E and TR21 
samples, respectively; [
3
H] MRE3008F20 saturation assays revealed A3ARs with KD of 
1.2±0.2 and 0.9±0.1 nM, and Bmax of 168±20 and 95±10 fmol/mg of protein in E and TR21 
samples, respectively (Fig. 5B). Scatchard plot analysis revealed the presence of an high 
affinity binding site for each radioligand as suggested by the linearity of the lines. Computer 
analysis of the data failed to show a significantly better fit to a two site than to a one site 
binding model, suggesting that under our experimental conditions, there was, primarily, a 
single class of high affinity binding sites. 
Cell morphology 
Primary cultures obtained from CV exhibited a population of embryonal MCs, as revealed by 
positive immunostaining towards CD13, CD73, CD90 and CD105, while hematopoietic and 
endothelial cell markers were undetectable (CD14, CD31, CD34, CD45). Flow cytometry 
demonstrated culture contamination by non-MC cells of less than 5% (Fig. 6). 
AR mRNAs in CVMCs from E and A pregnancies 
AR mRNAs were investigated in CVMCs from E and TR21 pregnancies. The order of 
expression detected in both was A2B>A1>A2AAR. A3AR was revealed after 37–38 PCR 
cycles, suggesting low levels of expression. A1ARs were found to be downregulated in MCs 
of TR 21, (0.51±0.05) in comparison to euploid MCs; A2BAR was reduced in TR 21 
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(0.52±0.05); as for A2AARs, they were expressed at similar levels to E in TR 21 (0.95±0.1) 
(Fig. 7A). CD73 expression was similar in E and A cells (0.90±0.1) (Fig. 7B). 
AR proteins in E and A MCs 
Western blot analysis was used to quantify ARs in MCs from CV of E and TR21 pregnancies. 
A1 and A2B ARs were found to be downregulated in TR21 MCs with respect to E MCs. 
A2AARs and CD73 were not significantly altered in TR21. A3ARs were expressed at 
lowlevels in both E and A cells (Fig. 8).  
ARs increase NO secretion in MCs 
We evaluated NO production by MCs after treatment with the nonselective agonist NECA 
under hypoxic conditions (24 h). NECA raised NO levels by 459±50% and 466±48% in E and 
TR21 cells, respectively. Basal NO levels were slightly higher in TR21 than in E cells (39±4 
and 49±5 μM in E and TR 21 cells, respectively) (Fig. 9A). The NECA effect was strongly 
reduced by PSB 36 and SCH 442416, selective antagonists of A1 and A2A ARs, respectively, 
suggesting the involvement of A1 and A2A subtypes, and reduced to a lesser extent by PSB 
603, selective antagonist of A2B (Fig. 9A). The effect of AR siRNAs was also tested. A1AR 
siRNA was the most potent at reducing NECA-induced stimulation of  NO levels, followed 
by A2A and A2BAR siRNAs (Fig. 9B). siRNA of HIF-1α greatly reduced NECA-stimulated 
NO increase, suggesting that ARs were acting through HIF-1α modulation (Fig. 9C). After 48 
and 72 h posttransfection with siRNA targeting each AR and HIF-1, protein levels were 
significantly reduced (Fig. 10A); the specificity of a given siRNA to the other AR subtypes is 
also shown in Fig. 10B. We therefore evaluated HIF-1α accumulation after incubation of E 
and TR21 MCs with NECA under hypoxia (2 h). NECA stimulated HIF-1α accumulation in 
both cell types, confirming the involvement of this transcription factor (Fig. 11). 
ARs stimulate VEGF secretion in MCs 
We tested VEGF production by MCs after treatment with NECA under hypoxia (24 h). 
NECA increased VEGF levels in a dose-dependent fashion by 314±32% and 330±35% in E 
and A cells, respectively. TR21 cells presented a lower basal level of VEGF (222±26 pg/ml in 
TR21 vs 404±52 pg/ml in E cells), and NECA showed a lower affinity for stimulation of 
VEGF secretion in TR21with respect to E cells (EC50 245± 26, 480±50 nM in E and TR21, 
respectively). The NECA effect was strongly reduced by PSB603 (300 nM), suggesting the 
involvement of A2BAR, and to a lesser extent by the A2A antagonist SCH442416 (25 nM), but 
not by PSB36 (50 nM) the A1 antagonist (Fig. 12A). The effect of AR siRNAs was also 
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tested. A2BAR siRNA produced the most potent reduction of NECA-induced stimulation of 
VEGF, followed by A2AAR siRNA, while A1 siRNA has no effect (Fig. 12B). Treatment with 
nitric oxide synthase antagonist L-NG-Nitroarginine methyl ester (L-NAME 150 μM) did not 
reduce NECA-stimulated increase in VEGF, suggesting that ARs were not acting through NO 
production (data not shown). The effect of NECA on VEGF was also observed on mRNA 
(2.6± 0.2-fold increase) (Fig. 12C). 
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Discussion 
 
Human reproduction is a complex process prone to failure, and several mechanisms, including 
angiogenesis, inflammatory and immune-related processes, have been considered as possible 
mediators of SA. Recently, it has been reported that aberrant maternal inflammation 
associated with SA is closely linked to deficient placental perfusion (Renaud et al., 2011). 
Emerging evidence also suggests that Ado, a proangiogenic nucleoside and a sensor of 
overactive immunity and inflammation, may be involved in determining pregnancy outcome 
(Hitoglou et al., 2004; Blackburn et al., 1999; Perni et al., 2009). In order to elucidate which 
ARs may affect the success of this event, we evaluated their expression in TR21, 
chromosomal abnormalities that very often end in abortion and may therefore represent a 
good model for elucidating the mechanism regulating miscarriage. Our findings show, for the 
first time, a reduction in A1, A2B and A3 ARs in CV biopsies obtained from TR21, in 
comparison to those from euploid pregnancies as evaluated by both western blotting and 
saturation binding experiments. The A2B antibody reveals a band of 50 kDa, substantially 
higher than theoretical molecular weight of this receptor subtype. As it has been previously 
demonstrated that 50–55 kDa immunoreactivity detected in many tissues may not represent 
the A2BAR we evaluated its specificity in transfected and untransfected Chinese hamster 
ovary (CHO) cells (Linden et al., 1999). Our data show that the A2B antibody was specific for 
A2BARs, according to literature data (von Versen-Höynck et al., 2009) and revealed a 
decrease in receptor density in TR21 CV. In order to quantify the affinity and density of ARs, 
saturation binding studies were performed. In CV, the ARs affinities were in the nanomolar 
range and the receptor densities of A1, A2B and A3 subtypes were decreased in TR21 samples. 
Even though DPCPX and ZM 241385 used as A1 and A2A radiolabeled ligands can also bind 
A2BARs, in the range of concentrations investigated we detected a single class of high affinity 
binding sites. Similar results have been observed in a recent paper by Varani in human 
synoviocytes expressing all four ARs (Varani et al., 2010).We therefore went on to further 
investigate ARs expression in CV MCs, which are routinely withdrawn for genotype analysis. 
Accordingly, we found, also for the first time, a reduction of A1 and A2B ARs in A MCs, 
whilst A3AR was expressed at very low levels in both E and A samples; this suggests that it 
may be more relevant in other cell types e.g. in preeclampsia (PE), A3AR expression has been 
found to be upregulated in trophoblasts, where it regulates MMP-2/9 expression (Kim et al., 
2008). As a whole, these data support the hypothesis that both A1 and A2B AR gene products 
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may positively regulate normal pregnancy. Indeed, A1AR has been reported to play an 
essential role in protecting the embryo against hypoxia and intrauterine stress (Wendler et al., 
2007; Rivkees and Wendler, 2011; Buscariollo et al., 2011). As for A2BARs, it is known to be 
involved in increasing angiogenesis through modulation of VEGF, and its genetic loss has 
recently been found to increase platelet aggregation, suggesting it has a beneficial effect in 
vascular injury (Grant et al., 1999; Feoktistov et al., 2002; Yang et al., 2010). A2BAR is also 
involved in chorionic vasoconstriction,with pathophysiological implications for PE and 
vascular diseases (Donoso et al., 2005). Since TR21 placentae are known to feature 
trophoblastic hypoplasia and hypovascularity, we investigated the potential role played by 
ARs in NO and VEGF regulation in both TR21 and normal pregnancies (Pipitone et al., 
2003); previously, the four ARs had been linked to the angiogenic actions of Ado in 
endothelial cells, smooth muscle, fibroblasts, monocytes, macrophages, mast and foam cells, 
all of which are recognized as important sources of proangiogenic factors (George et al., 
2010; Gessi et al., 2010; Wendler et al., 2007; Clark et al., 2007). We found slightly higher 
NO content in MCs from TR21 pregnancies than in E cells; A1 followed by A2A ARs were 
shown to increase NO production in an HIF-1- dependent fashion,with A2BAR only playing a 
minor role, confirming previous reports (Lima et al., 2010; Vàsquez et al., 2004). In contrast, 
A2BAR appeared to be the main subtype involved in VEGF secretion, as indicated by the 
affinity of NECA and the antagonizing effect mediated by both specific blockers and siRNA 
of ARs. A2AAR also contributed to VEGF secretion according to literature data (Fredholm et 
al., 2011). We found reduced VEGF in TR21 with respect to E cells; this was reversed by 
NECA stimulation, albeit with a lower affinity. These low levels of VEGF production, in 
addition to the higher NO content, have previously been reported in TR21 stem cells, and may 
be attributed to the fact that the candidate Down syndrome region gene lies on chromosome 
21 and encodes a negative regulator of VEGF–calcineurin signaling (Tranquilli et al., 2003; 
Salvolini et al., 2011; Baek et al., 2009). Furthermore, NO production, the main vasodilator in 
pregnancy, has been suggested as a compensatory response for restoring proangiogenic 
conditions in hypoxic MCs. 
As a whole, our data show that the Ado transduction cascade is disturbed in TR21 by two 
major anomalies, namely downregulation and reduced expression of A2B and A1 ARs. Such 
anomalies may negatively affect pregnancy to varying degrees; based on the literature, as well 
as our results, pregnancy can be interpreted as a vascular phenomenon whose destiny 
depends, among other factors, on the degree of disruption of each of the two ARs, which may 
be implicated in a range of complications, including SA, fetal malformation, fetal growth 
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restriction and preeclampsia (Vesce et al., 2002; 2001; 1997). Accordingly, stimulation of 
ARs, particularly A1 and A2B, may turn out to improve fetoplacental perfusion by increasing 
NO and VEGF. Our results also suggest that A1ARs and A2BARs may be useful as biomarkers 
to provide an early indication of SA risk, and, last but by no means least, lay the foundations 
for future studies investigating the molecular causes of miscarriage (Gessi et al., 2012). 
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Figures Legend 
 
Figure 5: Expression levels of A1, A2A, A2B, A3AR proteins in E and TR21 CV. 
Representative Western blot analyses of ARs in CV biopsies from women with E (line 2) and 
TR (line 3) pregnancies at 12 weeks of gestation. CHO cells transfected with the  different 
ARs were loaded as positive control (line 1). Histograms represent % decrease with respect to 
E pregnancies. Densitometric quantification of Western blots is the mean±SE values (N=4 for 
each group) ∗P<0.01 vs E CV. (A); Saturation curves of [3H]DPCPX, [3H]ZM 241385, [3H] 
MRE 2029 F20 and [
3
H]MRE 3008 F20 binding to A1, A2A, A2B, A3ARs in CV biopsies from 
E (N=13) and TR21 pregnancies (N=10) (B).Specific (■) and nonspecific equilibrium binding 
(▲) were determined as described in the methods. Each value represents the mean±SEM of 
experiments performed in duplicate. 
Figure 6: Immunophenotyping by flow cytometry analysis of purified CVMCs. Cell surface 
expression of MSC (CD13, CD73, CD90 and CD105), myeloid (CD14, CD45) and 
endothelial (CD31, CD34) markers is reported. The number of positive cell is reported in each 
diagram as % of total gated cells (> 10,000 events were analyzed). As negative control, cells 
were also stained with isotype-matched irrelevant antibody fluorescence (Irr.-FITC and 
Irr.PE). A representative sample is reported (N = 3). 
Figure 7: Expression levels of A1, A2A, A2B AR and CD73 target genes in E and TR21 
CVMCs. Histograms showing the content of AR (A) and CD73 (B) mRNA in E (N = 13, 
black) and TR21 (N = 8, white) MCs. Data were expressed as percentage of β-actin 
expression. *P < 0.01, vs. the corresponding receptor in E cells. 
Figure 8: Expression levels of A1, A2A, A2B, A3AR and CD73 proteins in E and TR21 
CVMCs. Representative Western blot analyses of ARs and CD73 in MC cells from euploid 
and TR21 pregnancies at 12 weeks of gestation. Histograms represent % decrease with 
respect to E pregnancies. Densitometric quantification of Western blots is the mean ± SE 
values (N = 3 for each group). ∗P < 0.01 vs E CV. 
Figure 9: NECA-stimulated NO secretion in E (white) and TR21 cells (black). NO levels in 
MC treated with 1 μM NECA in the absence and presence of 50 nM PSB 36, 25 nM SCH 
44216 and 300 nM PSB 603 (A) and with specific siRNAs of A1, A2A, and A2B ARs (B). 
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Effect of HIF-1α siRNA on NO secretion (C). *P < 0.05 vs. the corresponding control (E and 
A cells without NECA) and **P < 0.05 vs. the corresponding NECA (N = 5 for each group). 
Figure 10: ARs and HIF-1α silencing by siRNA transfection in MC. Western blot analysis 
using anti A1, A2A, A2B and HIF-1 polyclonal antibodies of protein extracts from MC treated 
with siRNA and cultured for 24, 48 and 72 h (A). Specificity of Ado receptors siRNAs (B). 
Western blot analysis using anti A1, A2A, and A2B receptor polyclonal antibodies of protein 
extracts from MC transfected with control ribonucleotides (ctr.) or with siRNA of each AR 
subtype and cultured for 72 h. Tubulin shows equal loading protein. 
Figure 11: Effect of NECA on HIF-1α accumulation in E and TR21 cells. Stimulation of 
HIF-1α accumulation by NECA (B,D) in CVMC E (A,B) and TR21 (C,D) by means of 
immunofluorescence analysis; bar graph data (E), expressed as mean ± SE percentage of total 
HIF-1α staining (N = 3 for each group); *P < 0.05 vs. the corresponding control (E and A 
cells without NECA). Figure shows 1 representative experiment. 
Figure 12: NECA-stimulated VEGF secretion in E (white) and TR21 cells (black). VEGF 
levels in CV-derived MCs treated with 1 μM NECA in the absence and in the presence of 50 
nM PSB 36, 25 nM SCH 44216 and 300 nM PSB 603 (A), and with specific siRNAs of A1, 
A2A, and A2B ARs (B). Induction of VEGF mRNA by NECA in healthy (white) and TR21 
(black) cells (C); *P < 0.05 vs. the corresponding control (E and A cells without NECA) and 
**P < 0.05 vs. the corresponding NECA (N = 5 for each group). 
Supplemental Figure 1: Specificity of the A2B antibody. Full-length Western blot showing 
all band of A2BAR in untransfected CHO cells (negative control), CHO cells transfected with 
A2BAR (positive control) and in CV from E and TR21 pregnancies  
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Introduction 
 
Astrocytes are the predominant cell type in the CNS. They function to maintain normal brain 
physiology, neuronal homeostasis and plasticity. In addition, astrocytes become reactive 
following injury to the CNS and serve important modulatory roles during CNS inflammation 
(Giaume et al., 2007). Inflammation plays a critical role in the pathogenesis of many CNS 
disorders, such as stroke, ischemia, trauma and neurodegenerative diseases. Several works in 
the field of stroke and brain ischemia has shown the relevance of the inflammatory response 
accompanying necrotic brain injury (Wang et al., 2007). Brain ischemia triggers inflammatory 
responses due to the presence of necrotic cells, generation of reactive oxygen species and 
production of inflammatory cytokines even within neurons. After cerebral ischemia, 
astrocytes become a major source of inflammatory mediators such as cytokines, chemokines 
and iNOS. These factors are involved in cellular degeneration under neuroinflammatory 
conditions which are associated with pathologies such as ischemia, stroke, CNS injury and 
neurodegenerative disorders (Vexler et al., 2006). Hypoxia has Janus-faced effects on 
astrocytes and their ability to support neuronal viability (Vangeinson and Rempe, 2009). For 
example, hypoxia preconditioning mediates astrocyte-dependent protective effects on neurons 
(Chu et al., 2010). However, hypoxia in the presence of inflammatory signalling triggers 
processes in astrocytes, that augment neuronal death (Vangeinson et al., 2008). A principal 
molecular mechanism, by which cells respond to hypoxia, is the activation of the transcription 
factor HIF-1α. During hypoxia HIF-1α protein is stabilized and heterodimerizes with HIF-1β 
to form HIF-1, subsequently regulating the expression of target genes (Semenza, 2002). HIF-
1 plays an important role in brain development and hypoxic-ischemic brain injury, and the 
molecule exhibits both neuroprotective as well as neurotoxic properties depending on the 
duration of hypoxia, the type of pathological stimuli and the cerebral cell type involved 
(Sharp and Bernaudin, 2004; Karovic et al., 2007; Fan et al., 2009). A myriad of factors are 
involved in the regulation of HIF-1α expression (Semenza, 2002). Exposure of macrophages 
to bacteria or LPS leads to HIF-1 accumulation even under normoxic conditions (Frede et al., 
2006; Jantsch et al., 2011). As for glial cells, it has been suggested that LPS increases HIF-1 
activity in microglia and oligodendrocytes, whilst no data exist in primary astrocytes (Oh et 
al., 2008; Yao et al., 2008; 2013).  
Ado, is a signalling molecule that has been shown to dampen hypoxia-induced inflammation 
in many models of disease (Poth et al., 2013) and plays a neuromodulatory role in the CNS 
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(Fredholm, 2012). Activation of ARs in glial cells seems to mediate many protective effects 
on the surrounding neurons after hypoxic insult (Daré et al., 2007). In particular, Ado released 
by astrocytes, through A1ARs stimulation, contributes to hypoxia-induced modulation of 
synaptic transmission, inhibits reactive astrogliosis and regulates glutamate uptake (Pascual et 
al., 2005; Martin et al., 2007; Wu et al., 2011). In addition, A1 and A3 subtypes protect 
astrocytes from hypoxic damage, by reducing ATP release and apoptosis (Björklund et al., 
2008) and A3AR activation inhibits inflammatory cell migration (Choi et al., 2011). It is well 
recognized that Ado affects HIF-1 induction in peripheral inflammatory cells like tumor cells  
(Merighi et al., 2005, Gessi et al., 2008), macrophages (De Ponti et al., 2007, Ramanathan et 
al., 2007; Ernens et al., 2010) and foam cells (Gessi et al., 2010) by activating different 
receptor subtypes. However no data are available concerning the regulation of HIF-1 by Ado 
in primary astrocytes.  
 
Astrocyte 
 
Work over the past decade indicates that astrocytes play multiple active roles in acute and 
chronic neuronal diseases such as seizure, stroke, and ischemia (Kimelberg and Nedergaard, 
2010). Unlike microglia and oligodendrocytes, astrocytes form physically coupled networks 
mediated by gap junctions, which, among other functions, facilitate intercellular transmission 
of Ca
2+
 signaling and exchange of cytosolic contents, and display oscillations in ion 
permeability through astrocytic networks. Although astrocytes are typically immune labeled 
by glial fibrillary acidic protein (GFAP), GFAP immunoreactivity labels only major branches 
and processes of astrocytes. The actual territory occupied by an astrocyte is much larger than 
that revealed by GFAP immunostaining. Of note, each astrocyte forms a non-overlapping 
territory or domain (Iadecola and Nedergaard, 2007), which collectively resemble a lattice 
framework, appearing crystalline in nature. Although the implications of this organization are 
not fully understood, it becomes lost when astrocytes transition to reactive states (Oberheim et 
al., 2008). In addition, astrocytes have extensive contacts with both synapses and cerebral 
blood vessels, and control the increase in blood flow evoked by synaptic activity. The 
astrocyte-mediated blood flow increase is fundamental to the blood oxygen-level-dependent 
(BOLD) signal (Iadecola and Nedergaard, 2007). It is estimated that a single astrocyte can 
enwrap 140,000 synapses and 4 to 6 neuronal somata, and can contact 300 to 600 neuronal 
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dendrites in rodents (Bushong et al., 2002; Gao and Ji, 2010; Oberheim et al., 2009). A close 
contact with neurons and synapses makes it possible for astrocytes not only to support and 
nourish neurons but also to regulate the external chemical environment during synaptic 
transmission. Recently, it has been shown that receptor mediated increases in astrocytic Ca
2+
 
can modulate neural network activity by active uptake of extracellular K
+
 (Wang et al., 2012). 
Because the extracellular concentration of K
+ 
is an important determinant of the resting 
membrane potential and thereby of neuronal activity, active uptake of K
+
 represents a simple 
yet powerful tool for rapid modulation of neural networks (Ji et al., 2013) 
 
     
Figure 13:Schematic representations that summarize, a) astrocyte functions in healthy CNS, and b) triggers and 
molecular regulators of reactive astrogliosis (Sofroniew and Vinters, Acta Neuropathol;119:7-35; 2010) 
 
Biochemical and structural changes of astrocytes during neuroinflammation represent a 
physiological response to CNS injury to minimize and repair the initial damage. Nevertheless, 
sustained inflammatory responses might be driven by positive feedback loops between 
microglia and astrocytes under conditions of severe and/or prolonged brain insults, thus 
providing detrimental signals that can compromise astrocytic and neuronal functions and lead 
to chronic neuroinflammation (Glass et al., 2010; Sofroniew and Vinters, 2010). Early stages 
of disease are associated with the activation of common inflammatory pathways, involving 
microglia and astrocytes activation, and the release of pro-inflammatory cytokines and other 
inflammatory mediators that regulate astrocytic hypertrophy and proliferation (Fig.13). 
Evidence of neuroinflammatory processes has been found in several neurological disorders, 
such as ischemia, spinal cord injury (SCI) and psychiatric/mood disorders (Okada et al., 2006; 
Verkhratsky et al., 2013), as well as in neurodegenerative diseases including Alzheimer's 
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disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinocerebellar 
ataxia type 1 (SCA1), Huntington's disease (HD) and multiple sclerosis (MS) (Glass et al., 
2010). Inflammatory processes are the hallmark of both acute and chronic neurodegenerative 
diseases. Glial reaction involves activation of receptors, such as Toll-like receptors (TLR), 
transcription factors (NF-kB, AP-1, etc.) and signaling molecules (p38MAPK, JNK, 
JAK/STAT3, etc.) of common inflammatory pathways, as well as alteration of protein 
expression (GFAP, vimentin, aminoacid transporters, receptors, etc.) and enzymes, like COX-
2, NOS, MMPs, etc. (Glass et al., 2010). For instance, TLRs are associated with the activation 
of microglia and astrocytes by amyloid- and the downstream inflammatory response in AD 
models. Therefore, molecules that antagonize or modulate sensors (TLR, etc.), transducers 
(NF-kB,AP-1, etc.) and effectors (TNFα, COX-2, etc.) of the inflammatory response may 
represent a new prospective for disease-modifying therapies (Colangelo et al., 2014). 
Astrocytes: targets for neuroprotection in CNS diseases 
Brain ischaemia induces a cascade of events that involve a loss of glucose and oxygen, 
membrane depolarization, and Glu (glutamate) release, leading to excitotoxicity (Badawi et 
al., 2012). Brain tissue viability after insult depends in part on astrocyte survival and 
functioning. In hypoxia and hypoxic related injuries to the brain, astrocytes although 
moderately resilient to injury undergo changes that compromise their abilities to provide 
support and can even act as executioners of cellular demise. Astrocytes themselves in in vitro 
models can survive severe hypoxia for up to 96 hours and anoxia for 12-24 hours (Yu et al., 
1989; Kelleher et al., 1993; Sochocka et al., 1994). In Middle Cerebral Artery Occlusion 
(MCAO) rat models, astrocytes experience morphological changes and swelling as early as 30 
minutes after occlusion, followed by an increase in GFAP reactivity by six hours and 
astrocyte death at 24 hours (Garcia et al., 1993). Astrocytes in regions totally deprived of 
blood flow undergo rapid necrosis within an hour. Similarly protoplasmic astrocytes in the 
peri-infarct areas exhibit disrupted cellular processes and cell shrinkage, while fibrous 
astrocytes seem to form the classic glial scar surrounding the necrotic tissue of the core 
(Lukaszevicz et al., 2002). The differences between in vivo and in vitro observations 
regarding astrocyte viability are likely the result of shifts in extracellular ion concentrations 
and pH. Indeed astrocytes in culture that are exposed to a combination of hypoxia and 
acidosis die rapidly compared to hypoxia treatment alone (Swanson et al., 1997). While 
astrocyte survival is important to the ultimate cellular fate of neurons, astrocyte functioning 
following hypoxia can cause changes in the extracellular environment that will alter neuronal 
viability.   
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It is likely that the Janus roles of astrocytes in response to hypoxia will depend on which 
physiological cues are activated when, and in response to which toxic stimuli. Perhaps 
astrocytes when activated moderately by sublethal toxic stimuli-including hypoxia, can 
activate protective cues, while prolonged exposure to hypoxic stimuli will promote the 
deleterious effects of astrocytes resulting in inflammation, cyotoxic release of molecules and 
loss of the protective buffering roles. Despite the many adaptive effects of astrocytes in injury 
and normal physiology, astrocytes are also capable of regulating other less desirable functions 
that could actually perpetuate damage. Upon injury astrocytes can become highly activated, 
increase GFAP and induce gliosis. Activated astrocytes will then go through a number of 
morphological and biochemical changes that can result in the release of toxic mediators, or 
simply limit their ability to mediate their protective functions. Interestingly, recent evidence 
in other injury models has begun to suggest ways in which astrocytes can mediate pathology 
in the CNS. For instance, a mutation in Superoxide dismutase (SOD1), previously linked to 
ALS, was found to mediate toxicity through astrocytes. Astrocytes with mutated SOD1, were 
capable of inducing non-cell autonomous death of motor neurons, while expression of 
mutated SOD1 in neurons was not toxic to the neurons themselves. These researchers found 
that death was induced through a secreted factor, which induced a BAX dependent cell death 
pathway in neurons (Nagai et al., 2007). Others have identified mitochondrial dysfunction as 
the mechanism in astrocytes, downstream of mutated SOD1, which causes motor neuron 
toxicity. Mitochondria from these astrocytes displayed impaired respiratory function, 
decreased oxygen consumption, lack of ADP-dependent respiratory control, decreased 
mitochondrial membrane potential, and increased production of superoxide radicals (Cassina 
et al., 2008). Astrocytes also play a key role in regulating the blood-brain barrier (BBB) 
integrity in the cerebral vasculature. They are also capable of releasing Ca
2+
 waves which are 
stimulated by ATP (Arcuina et al., 2002). Increases in Ca
2+
 in the astrocyte cell body are 
followed by Ca
2+
 increases in astrocyte endfeet and subsequent dilation of small arterioles in 
stimulated slice preparations (Zonta et al., 2003). As blood flow to the brain is reduced in 
stroke and other ischemic injuries, astrocytes are able to communicate these changes to 
neurons (Vangeinson and Rempe,2009). 
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Hypoxia Inducible Factor 
 
Initially identified as a regulator of erythropoietin (EPO) production, HIF is recognized as a 
key modulator of the transcriptional response to hypoxic stress. Besides its adaptive function 
in cellular stress responses, recent work has also revealed important roles for HIF in both 
physiological and pathological processes (Majmudar et al., 2010). 
HIFs are obligate heterodimers consisting of an O2-labile α subunit and a stable β subunit. 
Mammals possess three isoforms of HIFα, of which HIF-1α and HIF-2α (also known as 
EPAS1) are the most structurally similar and best characterized. HIF-3α (or IPAS) exists as 
multiple splice variants, some of which inhibit HIF-1α and HIF-2α activity in a dominant 
negative fashion (Kaelin and Ratcliffe, 2008). HIF-1α is expressed ubiquitously in all cells, 
whereas HIF-2α and HIF-3α are selectively expressed in certain tissues, including vascular 
endothelial cells, type II pneumocytes, renal interstitial cells, liver parenchymal  cells, and 
cells of the myeloid lineage (Bertout et al., 2008). 
HIF-1 
HIF-1 is a heterodimetric complex consisting of a constitutively expressed β subunit (also 
known as the aryl hydrocarbon receptor nuclear translocation, ARNT) and a hypoxia 
inducible subunit, α subunit (Wang et al., 2002). Both subunits belong to the basic helix-loop-
helix (bHLH)- PER-ARNT-SIM (PAS) protein family. The bHLH and PAS motifs are 
required for dimerization between HIF-1α and HIF-1β. HIF-1α possesses a unique oxygen-
dependent degradation domain (ODDD), which mediates oxygen-regulated stability, and two 
transactivation domains, N-terminal (N-TAD) and C-terminal (C-TAD) (Pugh et al., 1997; 
Ruas et al., 2002). Under hypoxia, HIF-1α is stabilized and translocated to the nucleus where 
it dimerizes with HIF-1β. The activated HIF-1 complex subsequently binds to hypoxic 
response elements (HREs) in the regulatory regions of genes and recruits co-transactivation 
factors such as CBP/p300 (CREB (cAMP-response element-binding protein)-binding 
protein/E1A-binding protein]. It induces transcription of more than a hundred genes with 
various functions. The activity of HIF-1 is mainly controlled through regulating the protein 
level of HIF-1α (Ke and Costa, 2006). Although the transcription and the synthesis of HIF-1α 
are constitutive, its protein degradation and transcriptional activity are regulated by post-
translational modifications on different amino acid residues in different domains. HIF-1α 
protein can be hydroxylated. Prolyl hydroxylation determines HIF-1α degradation in 
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normoxia. HIF-1α is hydroxylated on the prolyl residues 402 and 564 within the ODDD 
(Hewitson et al., 2004). The hydroxylation is mediated by a family of prolyl hydroxylases, 
namely PHD1, PHD2, and PHD3 (Srinivas et al., 1999), among which PHD2 has the highest 
specificity for hydroxylation of HIF-1α (Hewitson et al., 2004). These PHD enzymes are 2-
oxoglutarate-dependent dioxygenases and require oxygen as well as Fe
2+
 as cofactors (Ivan et 
al., 2001; Jaakkola et al., 2001). Hydroxylation promotes interaction of HIF-1α with the von 
Hippel-Lindau (pVHL) ubiquitin E3 ligase complex (Maxwell et al., 1999; Ohh et al., 2000). 
HIF-1α is thereby poly-ubiquitinated and degraded by the 26S proteasome (Salceda and Caro, 
1997; Min et al., 2002). At the transcriptional level, oxygen availability enables hydroxylation 
of the asparagine residue 803 in the C-TAD of HIF-1α by factor inhibiting HIF (FIH-1), 
which blocks the association of HIF-1α with transcriptional co-activators CBP/ p300 and thus 
inhibits its transcriptional activity (Lando et al., 2002). HIF-1α can be acetylated on lysine 
residue 532 in the ODDD domain. Acetylation may affect HIF-1α hydroxylation and 
ubiquitination. K532 acetylation by the ARrest-Defective-1 (ARD-1) enhances the interaction 
between HIF-1α and pVHL and, thus, leads to increased ubiquitination and concomitant 
proteasomal degradation (Jeong et al., 2002). Direct phosphorylation on threonine 796 by 
MAPK has been identified as a modification able to increase HIF-1 activity (Gradin et al., 
2002). One mechanism to explain the increased transcriptional activity is that HIF-1β binds 
preferentially to the phosphorylated form of HIF-1α (Suzuki et al., 2001). Moreover, it has 
been reported that phosphorylation at T796 in HIF-1α increases the affinity of the interaction 
between HIF-1α and the transcriptional co-activator CBP/p300 (Lancaster et al., 2004). 
Consistent with this, it is found that phosphorylation of T796 prevents the hydroxylation of 
N803 by FIH (Dimova et al., 2009). Then, it has been suggested that direct phosphorylation 
of HIF-1α by MAPK is not correlated with its transcriptional activity, but that 
phosphorylation of the HIF-1α co-activator p300 by MAPK increases the interaction between 
the HIF-1α C-TAD and p300 (Brahimi-Horn et al., 2005). Inhibition of these phosphorylation 
sites has been shown to impair both transcriptional activity and the nuclear localization of 
HIF-1α. In addition, phosphorylation of HIF-1α by glycogen synthase kinase (GSK)-3β may 
target HIF-1α for proteasomal degradation (Dimova et al., 2009). HIF-1α can be oxidized. 
Hydroxyl radical and hydrogen peroxide can destabilize HIF-1α protein in both normoxic and 
hypoxic conditions (Huang et al., 1996; Liu et al., 2004). The oxidized HIF-1α protein might 
be recognized and degraded by the ubiquitin-independent 20S proteasomal pathway, which 
primarily degrades cellular oxidized proteins under oxidative stress conditions (Shringarpure 
et al., 2003). Therefore, in addition to the 26S proteasomal pathway, 20S proteasomal 
pathway may play an important role in the degradation of HIF-1α in ischemic conditions (Shi, 
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2009). Moreover, studies have revealed that S-nitrosation stabilizes HIF-1α protein and S-
nitrosation of cysteine 800 of HIF-1α promotes its interaction with CBP/p300, thus enhancing 
HIF-1α activation (Yasinska et al., 2003). Sumoylation of HIF-1α has been reported to 
regulate its protein level and transcriptional activity. Increasing the activity of RWD-
containing sumoylation enhancer (RSUME) could promote the sumoylation of HIF-1α by 
Ubc9 SUMO conjugase and stabilize HIF-1α during hypoxia (Carbia-Nagashima et al., 2007). 
However, desumoylation by SUMO-Specific Protease 1 (SENP-1) has been shown to be 
essential for the stabilization of HIF-1α  (Cheng et al., 2007). Sumoylation has also been 
found to work with ubiquitination to reduce HIF-1 protein level and transcriptional activity  
(Cheng et al., 2007; Berta et al., 2007; Zhang et al., 2011) 
HIF-2 
Shortly after the cloning of HIF-1α, a closely related protein, HIF-2α was identified and 
cloned (Ema et al., 1997; Flamme et al., 1997; Hogenesch et al., 1997; Tian et al., 1997). HIF-
2α shares 48% amino acid sequence identity with HIF-1α and accordingly shares a number of 
structural and biochemical similarities with HIF-1α (for instance, heterodimerization with 
HIF-1β and binding HREs). In contrast to ubiquitously expressed HIF-1α, HIF-2α is 
predominantly expressed in the lung, endothelium, and carotid body (Ema et al., 1997; Tian et 
al.,1998; Ke and Costa, 2006). 
HIF-3 
HIF-3α, which was discovered later, is also expressed in a variety of tissues, dimerizes with 
HIF-1β, and binds to HREs (Gu et al., 1998). In addition, a splice variant of HIF-3α, 
inhibitory PAS (IPAS), which is predominantly expressed in the Purkinje cells of the 
cerebellum and corneal epithelium, was subsequently discovered (Makino et al., 2001). IPAS 
possesses no endogenous transactivation activity; rather, it interacts with the amino-terminal 
region of  HIF-1α and prevents its DNA binding, acting as a dominant negative regulator of 
HIF-1 (Makino et al., 2001). However, IPAS can also be induced by hypoxia in the heart and 
lung, contributing to a negative feedback loop for HIF-1 activity in these tissues (Makino et 
al., 2002; Ke and Costa, 2006).  
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Figure 14: A systematic representation of HIF regulation under normoxic and hypoxic conditions (Singh et al., Cell 
Mol Neurobiol;32:491-507, 2012).  
 
Recently, there have been extensive efforts to explore the beneficial role of HIF in several 
neurological diseases such as cerebral stroke and AD. In response to lower oxygen 
concentration, HIF-1α accumulates and triggers the expression of several genes which initiate 
angiogenesis, erythropoiesis, vascular tone maintenance, mitochondrial function, cell survival 
following ischemic/hypoxic injury. There is growing evidence which shows that activation of 
HIF-1α offer protection in case of cerebral ischemia (Singh et al., 2012). 
  
95 
 
HIF-Regulated genes: Neuroprotection or Inflammation 
 
Vascular Tone 
During cerebral ischemia, the disturbance in vascular tone is one of the major consequences, 
which results in neuronal cell death. The iNOS is one such gene which is regulated by HIF-1 
and helps the cells to cope up with these adverse conditions (Singh et al., 2012). NO, serves 
as a signaling molecule and participates in a plethora of biological functions. In the 
mammalian brain, NO has been defined as an atypical neurotransmitter (Boehning and 
Snyder, 2003), being secreted by neurons and having direct effects on their electrical activity. 
More specifically, it has been postulated that NO serves as a retrograde messenger between 
the post- and the presynaptic elements in the most abundant excitatory synapses. It has been 
largely assumed that a neuronal Ca
2+
/calmodulin-regulated NO synthase (nNOS) consists in 
the principal isoform producing the NO that acts at the synapse (Arancio et al., 1996; 
Micheva et al., 2003). Another Ca2+/calmodulin-regulated NOS isoform is expressed 
primarily by endothelial cells, eNOS and is known to take part in blood flow regulation, 
although it has been proposed that NO produced by the cerebral vasculature also affects 
nearby neurons (Garthwaite et al., 2006). A third, “inducible” iNOS is expressed by glia cells, 
and acts in a Ca
2+
-independent manner (Aktan, 2004; Alderton et al., 2001). The involvement 
of this isoform in modulating neuronal activity has been largely ignored, as the prevailing 
viewpoint maintains that this enzyme is not detectable under normal conditions, but rather it 
is up-regulated by gene induction following detrimental events such as ischemia or 
inflammation (Aktan, 2004; Saha and Pahan, 2006), where NO participates in the regulation 
of inflammatory processes. Several studies over the years have pointed to a weak constitutive 
expression of iNOS in various brain regions, and raised the possibility of astrocytic-derived 
NO participating in physiological brain processes (Buskila et al., 2005; Chan et al., 2001, 
2003). iNOS is the only isoform whose activity is not dependent on the elevation of 
intracellular Ca
2+
 (Amitai, 2010). 
Vascular Endothelial Growth Factor 
The human and rodent VEGF genes  (Liu et al., 1995) and their activation are triggered by the 
HIF-1α binding (Forsythe et al., 1996). During cerebral ischemia, the damaged tissue tries to 
increase oxygen delivery by the induction of angiogenesis via VEGF. This hypothesis is 
supported by the fact that there is an increase in the number of microvessels in the infarct area 
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of brain at various survival times in stroke patients as compared with normal hemisphere 
(Krupinski et al., 1994). The VEGF and its receptors are upregulated in the brain by HIF-1α 
and 2α during 6 to 24-h post-ischemia (Singh et al., 2012). 
Glycolytic Enzymes 
Since ischemic disturbance in cerebral blood flow results in high oxygen and glucose 
starvation. Glucose is the only source of ATP generation by the neuronal cells in brain and 
needs to be supplied to meet its required amount. Hence, to overcome this unfavorable 
situation the neuronal cells have to fulfill the glucose demand by increasing the activity of 
glycolytic enzymes and Glucose transport (GLUTs), which enhance the concentration of 
glucose and thereby ameliorate neuroprotection. GLUT and glycolytic flow as a result of HIF-
1α activation by hypoxia has been linked to cell survival (Lawrence et al., 1996). It has been 
shown that there is an HIF-1α associated increase in GLUT1 expression, which starts from 
7.5 h and last up to 24 h after permanent MCAO (Bergeron et al., 1999). The study also 
provided evidence that there is an increased expression of HIF-1α dependent glycolytic 
enzymes in cingulate/retrosplenial cortex following permanent MCAO (Singh et al., 2012). 
A2BARs 
Previous studies had identified transcriptionally regulated alterations of A2BARs expression 
during hypoxia-elicited inflammation. These studies demonstrated selective induction of the 
A2BARs following exposure of  human vascular endothelia to ambient hypoxia. Additional 
studies investigating the promoter activity, functional chromatin binding, and HIF-1 loss-of-
function studies demonstrated a critical role of HIF-1 in mediating hypoxia-associated 
induction of the A2BARs (Kong et al., 2006). Other works demonstrated HIF-1–dependent 
induction of the A2BARs during myocardial ischemia (Eltzschig et al., 2012). This study 
indicated that increases in A2BARs following exposure to inflammatory stimuli involved 
alterations in mRNA stability (Eckle et al., 2014) 
 
Effect of adenosine in astrocytes 
 
Ado can modulate astrocyte functions in many ways (Fig. 15). Astrocytes are endowed with 
all the known subtypes of ARs and they control metabolism of carbohydrates, astrogliosis and 
the release of neuroactive substances (Ciccarelli et al., 2001). Not all effects are receptor 
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mediated. For example, Ado (and inosine)-mediated reduction of cell death in glucose 
deprived astrocyte cultures (Shin et al., 2002), appears to be due to intracellular formation of 
ribose-1-phosphate, which is able to fuel the intracellular ATP production (Jurkowitz et al., 
1998). By contrast, Ado-mediated rapid glycogenolysis followed by increased glycogen 
synthesis in primary astrocytes (Allaman et al., 2003), seems to be mediated by the A2BAR 
and involves transcriptional changes of genes encoding proteins regulating energy 
metabolism. Astrocytes respond to traumatic and chemical brain injury with morphological 
and biochemical changes, including reactive gliosis and astrocytic swelling, which are 
presumably independent processes (Aschner et al., 1998). Reactive gliosis consists in 
phenotypic alterations, increased size and number of astrocytes. This process involves the up-
regulation of enzymes and cytoskeletal proteins, e.g., GFAP and vimentin, as well as 
increased levels of TGF-β, nerve growth factor (NGF), basic-fibroblast growth factor (bFGF) 
and growth factor receptors, e.g., truncated forms of trkB. The elevated level of Ado that 
follows brain injury could critically modulate astrogliosis, as suggested by the increased 
number of GFAP-positive cells after microinjection of the Ado analogue 5′-(N-cyclopropyl)-
carboxamidoadenosine into rat cortex (Hindley et al., 1994). This effect was abolished by 
coinfusion of the A2AAR antagonist 1,3-dipropyl-7- methylxanthine (DPMX), indicating a 
role for A2AARs in regulating astrogliosis via Ado. In agreement, the A2AAR antagonist 5-
Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine 
(SCH58261) reduced the formation of reactive astrocytes induced by bFGF in astrocytes in 
vitro (Brambilla et al., 2003). Ado was also reported to stimulate “stellation”, i.e., astrocytic 
hypertrophy, in primary cultures, via activation of ARs and tyrosine dephosphorylation (Abe 
and Saito, 1998). Besides A2ARs, A3ARs may also mediate astrogliosis (Abbracchio et al., 
1998), whereas A1ARs inhibit astrocyte proliferation (Ciccarelli et al., 1994). Reactive gliosis 
is generally regarded as beneficial, because it involves the production of neurotrophins and it 
isolates the damaged tissue. However, its prolonged effects may enhance the production of 
toxic factors, such as NO and arachidonic acid metabolites (Neary et al., 1996). Indeed, 
astrogliosis is also observed in neurodegenerative diseases. Paradoxically, Ado at high 
concentration can induce astrocyte cell death by apoptosis in vitro, via mechanisms involving 
both the activation of the A3AR and Ado internalization and metabolism (Di Iorio et al., 
2002). The capability of high levels of Ado to induce apoptosis has been interpreted as a 
possible mechanism to limit excessive cell proliferation due to extensive reactive gliosis 
(Ciccarelli et al., 2001). This pathway may become a promising target for the development of 
therapeutic strategies to treat neurodegenerative conditions, such as Parkinson's disease. In 
some circumstances, e.g., ischemia and traumatic brain injury, the challenging insults cause 
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astrocytic swelling, consisting in volume changes in the absence of GFAP accumulation, 
increases in extracellular K
+
 concentration, and loss of L-glutamate, D-aspartate and taurine. 
Astrocytes produce a variety of factors that act as key mediators of immunity and 
inflammation. These include cytokines, chemokines, proteases, protease inhibitors, adhesion 
molecules and extracellular matrix (Dong and Benveniste, 2001 ). There is currently a great 
interest in investigating a possible role of Ado in the regulation of these factors. A recent 
study (Wittendorp et al., 2004) has demonstrated that stimulation of primary mouse astrocytes 
with the specific A3AR agonist CL-IB-MECA induces the release of the chemokine CCL2 
through a Gi protein-independent pathway. Thus, Ado acting on the A3AR appears to 
modulate the level of a chemokine that can exert both neuroprotective and detrimental effects. 
Ado is able to enhance the production of other important neuroprotective substances, such as 
NGF, TGF-β1 and S100 β, in cultured astrocytes via activation of A1ARs (Ciccarelli et al., 
1999, Schwaninger et al., 1997). The increase in IL-6 synthesis and secretion induced by Ado, 
instead, is inhibited by the nonselective ARs antagonist 8-(p-sulfophenyl) theophylline, but 
not by specific A1 or A2A antagonists (Schwaninger et al., 1997). Furthermore, signalling via 
A2BARs is influenced by interleukins in parallel with the generation of NGF (Fredholm and 
Altiok, 1994). Thus, Ado may augment the neuroprotective effects of astrocytes both via 
changes of the astrocyte metabolism and through pathways mediated by different ARs 
subtypes. However, high levels of Ado caused by prolonged or exaggerated exposure to 
pathological conditions may also exacerbate degenerative processes, leading to both astrocyte 
death and damage of neurons. It should be remembered that astrocytes are an important 
component of the BBB and are directly involved in the control of the BBB permeability via 
release of mediators. The factors participating in this regulation are for the most part unknown 
and Ado itself is a candidate. Experiments performed with an experimental BBB in vitro 
model have not supported the hypothesis of a major role of ARs subtypes in the regulation of 
the BBB permeability. Instead, they have suggested a role of the ENTs in the transport of Ado 
derivatives in astrocytes, providing a possible target for delivering synthetic compounds to the 
brain (Schaddelee et al., 2003; Daré et al., 2007). 
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Figure 15: Ado modulates a variety of astrocyte functions  
(Daré et al., Physiology & Behavior;92:15-20; 2007) 
 
Possible role of HIF, Astrocyte and Adenosine in neuroprotection 
 
HIF-1 promotes the production of Ado, because of  binding to the CD73 promoter and 
subsequent induction of CD73 transcript and protein levels (Eltzschig et al., 2004; Thompson 
et al., 2004). As such, hypoxia and inflammation are associated with increased production of 
Ado from its precursor molecules, thereby shifting the balance from proinflammatory ATP 
signaling towards anti-inflammatory Ado signaling (Poth et al., 2013). Ado binds to the 
presynaptic A1AR and lead to a decrease in Ca
2+
 influx. This further decreases the release of 
Glu and excitation of the NMDA receptors, thus preventing cellular damage caused by the 
subsequent increases in Ca
2+
 influx (Monopoli et al., 1998; Wardas, 2002). A study by Batti et 
al. (2010) has shown that the stabilization of HIF-1α through prolyl hydroxylase inhibition 
protected against Glu-induced damage in the hippocampus of the rat ischaemic brain mainly 
through Ado accumulation in response to hypoxia. A review article by Vangeison and Rempe 
(2009) clearly describes how hypoxia and HIF-1 can regulate various proteins, including 
connexin 43, CD73 and the ENT-1, which ultimately leads to enhanced Ado levels. Of these, 
both CD73 and ENT-1 have been shown to be regulated by HIF-1 in intestinal epithelia 
(Synnestvedt et al., 2002) and endothelial cells (Eltzschig et al., 2005) respectively. CD73 and 
ENT-1 are expressed in astrocytes (Vangeison and Rempe, 2009); therefore it is possible that 
HIF-1 can regulate their activity and increase Ado in astrocytes. In fact, it has been shown 
that Ado has a direct protective effect by reducing glucose deprivation-induced death on rat 
primary astrocytes (Shin et al., 2002) and an indirect action by decreasing human astroglioma 
cells damage following oxygen deprivation, through the preservation of ATP levels 
(Bjorklund et al., 2008; Badawi et al., 2012). 
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Aim of the thesis 
 
Astrocytes perform several functions that are essential for normal neuronal activity. 
Accordingly, they can influence neuronal survival during ischemia (Annunziato et al., 2013). 
Many clinically relevant diseases are characterized by significant tissue hypoxia (Semenza, 
2012; 2011; Eltzschig and Carmeliet, 2011). For example, ischemic tissue injury - such as that 
occurring in the context of myocardial infarction (Eckle et al., 2008; 2012), AKI (Grenz et al., 
2012), or stroke (Iadecola and Anrather, 2011) - is characterized by a profound increase in 
tissue hypoxia due to lack of arterial supply with oxygen from the blood (Eltzschig and 
Collard, 2004; Poth et al., 2013). In the present study, we discussed the modulation of HIF-1α 
by LPS in presence and in absence of hypoxia in primary murine astrocytes and then we 
examined whether Ado and Ado analogues could modulate HIF-1α accumulation and 
transcription in primary astrocytes activated by LPS in normoxic and hypoxic conditions. In 
the end the effects of hypoxia, LPS and Ado on the HIF-1α target genes, considering the main 
genes involved in hypoxia, ischemia, and inflammation have been studied.  
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Materials and Methods 
Drugs and materials 
A1, A2B, A3 ARs siRNAs, HIF-1α siRNA and anti-A2B and A3 ARs rabbit polyclonal 
antibodies were from Santa Cruz DBA (Milano, Italy). RNAiFect Transfection Kit was 
purchased from Qia-gen (Milano, Italy). Rabbit polyclonal antibody against A1AR was 
obtained from Alpha Diagnostic, Vinci Biochem (Firenze, Italy). Rabbit polyclonal anti-HIF-
1α was from Cayman, Vinci Biochem(Firenze, Italy). D-3-Deoxy-2-O-methyl-myo-inositol 1-
[(R)-2-methoxy-3-(octadecyloxy)propyl hydrogen phosphate] (SH5) was from Enzo-Life, 
Vinci Biochem (Firenze, Italy). 1,4-Diamino-2,3-dicyano-1,4-bis(2-
aminophenylthio)butadiene (U0126) and rabbit polyclonal anti-ERK1/2 were from Promega 
(Milano,Italy). Anti-beta actin and echinomycin were from Millipore (Milano, Italy). Anti-
GFAP and anti-CD11b antibodies were from Becton Dickin-son (Milano, Italy). Rabbit 
monoclonal anti-phospho-p44/42MAPK (Erk1/2) (Thr202/Tyr204), rabbit polyclonal 
phospho-Akt(Ser473), Akt and iNOS were from Cell Signaling, Euroclone (Milano, Italy). 
The Assays-on-demandTMGene expression Products for HIF-1 (Mm00468869_m1), GLUT-
1 (Mm00441480 _m1),GLUT-3 (Mm00441483_m1), GAPDH (Mm99999915_g1), 
hexokinase 2 (HK2) (Mm00443385_m1), VEGF (Mm00437304_m1), iNOS 
(Mm00440485_m1), A1(Mm01308023_m1), A2B(Mm00839292_m1) and 
A3(Mm00802076_m1) were purchased from Life Technologies Italia (Monza, Italy). PSB 36, 
Cl-IB-MECA and BAY 60-6583 were purchased fromTocris, Space Import-Export (Milano, 
Italy). Unless otherwisenoted, all other reagents were purchased from Sigma (Milano,Italy). 
Animals 
One-day-old Balb/c mice were obtained from Charles River (Calco, Italy). Animal care 
procedures were in accordance with the guidelines of the European Council directives 
(86/609/EEC) and were approved by the local Animal Care and Ethics Committee. 
Primary astrocyte cultures 
Briefly, after anaesthesia (Zoletil 100, 30 mg·kg-1, Virbac Laboratories, France) and 
decapitation, forebrains from newborn Balb/c mice were excised, meninges were removed 
and tissue was dissociated mechanically in 0.25% Trypsin-EDTA solution (Gibco, Life 
Technologies Italia, Monza, Italy). Cells were re-suspended in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% 
penicillin/streptomycin, then plated on poly-L-lysine-coated (5 mg·mL
-1
) 75 cm
2
 flasks 
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(Falcon; Euroclone, Milano, Italy). The culture medium was changed every 2-3 days. 
Astrocytes were obtained by treating the mixed cultures with cytosine arabinoside (AraC) for 
4 days (10 μM) as previously described (Saura et al., 2005; Hamby et al., 2006). Cells were 
grown in a humidified environment containing 5% CO2 at a constant temperature of 37°C. 
Astrocyte cultures were characterized by immunostaining with GFAP and the absence of 
microglial cells was confirmed using Mac-1 anti-CD11b antibody. LPS, a cell wall 
component of Gram negative bacteria, is a potent activator of glia. Hence, astrocytes were 
treated with 1 μg·mL-1 LPS under normoxia and hypoxia after exposure to Ado or receptor 
agonists for 30 min. All treatments with ARs agonists were performed in the presence of 
ADA. 
Hypoxic treatment 
Hypoxic exposures were done in a modular incubator chamber and flushed with a gas mixture 
containing 1% O2, 5% CO2 and balance N2 (MiniGalaxy, RSBiotech, Irvine, Scotland). 
Immunofluorescence analysis 
For HIF-1α detection cells were treated with Ado and LPS for 4 hours, under normoxia and 
hypoxia. Astrocytes were washed two times with PBS, fixed in 10% paraformaldehyde for 10 
min, permeabilized in a PBS solution containing 0.1% of Triton X-100 and incubated for 30 
min with PBS plus 5% goat serum and 0.5% bovine serum albumin. The cells were then 
incubated O.N. at 4°C in a humidified chamber with anti-HIF-1α Ab solutions (1:50) 
containing 0.5% of goat serum and 0.5% of bovine serum albumin in PBS. Excessive 
antibody was washed away with PBS and rabbit antibodies were detected with fluorescein 
isothiocyanate- labeled goat anti-rabbit IgG. Coverslips were stained with 4’,6- diamino-2-
phenyl-indole (DAPI), mounted in DABCO glycerol- PBS and observed on Nikon fluorescent 
microscope (Eclipse 50i) as previously described (Gessi et al., 2012). Images were analyzed 
using NIS Elements BR 3.0 software (Nikon Instruments Inc., Milan, Italy). Levels of 
normoxic and hypoxic HIF-1 in astrocytes were the basis for calculation of the additional 
LPS-mediated increase and for the inhibition played by Ado. The mean intensity of each cell 
was obtained from the cells pixels that had a higher intensity than that of the mean 
background intensity. A mean of 150 cells was analyzed for each condition at 40X 
magnification, at fixed time exposure. 
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Western blotting 
Whole cell lysates from murine astrocytes were prepared as described previously (Gessi et al., 
2010), whilst nuclear extracts were obtained by using the Nuclear Extract Kit (Active Motif, 
Vinci Biochem, Firenze, Italy) according to the manufacturer’s recommendations. The protein 
concentration was determined using a protein assay kit (Bio-Rad, Milano, Italy). Equivalent 
amounts of protein (40 µg) were subjected to electrophoresis on sodium dodecyl sulfate-
acrylamide gel. The gel was then electroblotted onto a nitrocellulose membrane. The 
membranes were probed with anti-A1 antibody  (1:1000 dilution), anti-A3 antibody (1:1000 
dilution), anti-HIF-1α (1:1000 dilution), anti-iNOS (1:1000 dilution) and anti-A2B (1:1000 
dilution). Filters were washed and incubated for 1h at room temperature with peroxidase-
conjugated secondary antibodies against rabbit IgG (1:2000 dilution). For detection of 
phosphorylated proteins antibodies specific for phosphorylated or total p44/p42 MAPK 
(1:1000 dilution), and phosphorylated or total Akt (1:1000 dilution) were used. Specific 
reactions were revealed with the Enhanced Chemiluminescence Western blotting detection 
reagent (Perkin Elmer, Milano, Italy). Actin (1:1000) was used to ensure equal protein 
loading. Please note that to better visualize the HIF-1 modulation by LPS and Ado in 
normoxia, the exposure times of western blots were higher for normoxia with respect to 
hypoxia.  
Densitometry analysis 
The intensity of each band in immunoblot assay was quantified using a VersaDoc Imaging 
System (Bio-Rad, Milano, Italy). Mean densitometry data from independent experiments 
were normalized to the results in control cells. 
Real-time RT-PCR 
Total cytoplasmic RNA was extracted by the acid guanidinium thiocyanate phenol method. 
Quantitative real-time RT-PCR assays of HIF-1, VEGF, GLUT1, GLUT3, HK2, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), iNOS and A2B mRNA were carried 
out using gene-specific fluorescently labelled TaqMan MGB probe (minor groove binder) in a 
MX3000P Stratagene Real-Time PCR System (M-Medical, Milano, Italy) (Gessi et al., 2010). 
For the real-time RT-PCR of the reference gene the endogenous control mouse β-actin kit was 
used, and the probe was fluorescent-labeled with VIC™ (Life Technologies Italia, Monza, 
Italy). Reactions were normalized to β-actin mRNA within the same sample using the ΔΔCT 
method. 
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small interfering RNA (siRNA) treatment 
Astrocytes were plated in six-well plates and grown to 50–70% confluence before 
transfection. Transfection of siRNA-A1, siRNA-A3, siRNA-A2B receptors and siRNA-HIF-1α, 
was performed at a concentration of 100 nM using RNAiFectTM Transfection Kit for 72 
hours. Cells were cultured in complete media, and then RNA and total proteins were isolated 
at 24, 48 and 72 h; after that realtime RT-PCR and western blot analysis of A1, A3, A2B ARs 
and HIF-1α proteins were performed. A randomly chosen non-specific siRNA was used under 
identical conditions as control (Merighi et al., 2012). 
Nitrite assay 
NOS activity was assessed indirectly by measuring nitrite (NO2
 -
) accumulation in the cell 
culture media using a colorimetric kit (Merck Chemicals, Nottingham, UK). At the end of the 
treatment period, the nitrite concentration in the conditioned media was determined according 
to a modified Griess method (Merighi et al., 2012). Briefly, the NADH-dependent enzyme 
nitrate reductase was used to convert the nitrate to nitrite prior to quantification of the 
absorbance, measured at 540 nm by a spectrophotometric microplate reader (Multiskan 
Ascent, Labsystems, Sweden). Sodium nitrite was used as the standard compound. 
MTS Assay 
The MTS assay was performed to determine astrocytes viability and proliferation according to 
the manufacturer's protocol from the CellTiter 96 AQueous One Solution (Promega) cell 
proliferation assay. Cells were plated in 24-multiwell plates; 500 μl of complete medium was 
added to each well with LPS, Ado and Ado + LPS.The cells were then incubated for 4, 8 and 
16 h in normoxia andhypoxia. At the end of the incubation period, MTS solution was added to 
each well. The optical density of each well was read ona spectrophotometer at 490 nm. 
Experiment was repeated three times. 
Statistical analysis 
All values in the figures and text are expressed as mean ± standard error (SE) of N 
observation (with N ≥ 4). N is equal to the number of mice from which the cells were derived. 
Data sets were examined by analysis of variance (ANOVA) and Dunnett’s test (when 
required). A P-value less than 0.05 was considered statistically significant. 
  
105 
 
Results 
 
LPS increases the expression of HIF-1α 
A kinetic analysis of HIF-1α modulation by LPS was performed in murine astrocytes. In 
normoxia LPS significantly increases HIF-1α accumulation starting after 4 hours (Fig. 16A). 
In hypoxia HIF-1α protein induction could be slightly seen after a 2h incubation, and maximal 
induction was attained between 4 and 8h. Treatment of astrocytes with LPS enhanced 
hypoxia-induced HIF-1α accumulation starting after 2h and peaking at 4h (Fig. 16B). LPS at 
concentrations from 0.01 to 1 μg/ml significantly increased the expression of HIF-1α in a 
dose-dependent manner in normoxia and hypoxia (Fig. 16C,D, respectively). 
Ado inhibits LPS-induced HIF-1α accumulation 
In normoxia Ado reduced LPS-induced HIF-1α accumulation in a dose dependent way (Fig. 
17A). The effect of the nucleoside was mimicked by the A1 agonist N(6)-cyclohexylAdo 
(CHA) and the A3 agonist Cl-IB-MECA in a dose-dependent manner, suggesting the 
involvement of A1 and A3 AR subtypes (Fig. 17B-C). The inhibitory effect induced by Ado, 
CHA and Cl-IB-MECA was also observed when LPS was incubated under hypoxic 
conditions (Fig. 17D-F). 2-p-(2- Carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoAdo 
hydrochloride hydrate (CGS 21680) decreased it only at 1 μM and BAY 60-6583 did not 
affect its level in both normoxic and hypoxic conditions (data not shown). Furthermore Ado 
did not significantly affect HIF-1α levels in hypoxia-exposed cells (data not shown). HIF-1α 
subunit is a pivotal transcription factor, that requires nuclear translocation for activity. We 
therefore analyzed the nuclear translocation of HIF-1α protein after treatment with LPS 
without and with Ado under normoxia and hypoxia by immunofluorescence. As demonstrated 
by figure 18, LPS displayed an increase in the intensity of the nuclear HIF-1α 
immunofluorescence in normoxia and the effect was reduced by the nucleoside. Similar 
results were observed in hypoxic conditions (Fig. 19). This inhibitory effect was also 
observed by CHA and Cl-IB-MECA in nuclear extract prepared from primary astrocytes 
incubated with HIF-1α antibody in both normoxic and hypoxic conditions (Fig. 20A,B, 
respectively). To confirm the involvement of A1 and A3ARs in this response, astrocytes were 
treated with 10 nM PSB 36 and 1 μM MRS 1523, A1 and A3 antagonists, respectively, before 
addition of 30 nM CHA and 100 nM Cl-IB-MECA in normoxia and hypoxia. As shown in 
figure 19, the inhibitory effect induced by CHA and Cl-IB-MECA was antagonized by PSB36 
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and MRS 1523, respectively, both in normoxia (A) and hypoxia (B). Antagonists alone did 
not modified HIF-1α basal levels (data not shown). As the effect of Ado agonists on LPS-
mediated HIF-1α increase in normoxic and hypoxic astrocytes were strictly similar, the 
inhibitory effect of Ado was evaluated in primary astrocytes exposed to A1 and A3 siRNAs 
under hypoxia. Silencing of primary astrocytes for 72 h reduced mRNA levels of A1 
(0.30±0.03) and A3 AR subtypes (0.25±0.03) in comparison to control cells transfected with 
non-specific random control ribonucleotides (siRNA scrambled, siRNActr) (1.0±0.1) and 
strongly reduced protein expression (Suppl. Fig. 2). In this condition both siRNAs of A1 and 
A3 ARs partially reverted the nucleoside inhibition of LPS mediated HIF-1α protein 
accumulation, suggesting the involvement of A1 and A3 subtypes in this effect (Fig. 20C and 
D, respectively). 
Mechanisms involved in the LPS-induced HIF-1α accumulation and effect of Ado 
We elucidated the mechanism underlying the enhanced accumulation of HIF-1α protein by 
LPS under normoxia and hypoxia before to evaluate the inhibitory effect exerted by Ado. To 
investigate transcriptional modulation of HIF-1α by LPS, cells were incubated with 
actinomycin D (ActD). As shown in figure 21A the effect of LPS on HIF-1α protein 
accumulation was completely abrogated after incubation with the inhibitor of transcription, 
both in normoxia (A) and hypoxia (B). As shown  in figure 21C, quantification of mRNA 
revealed a significant increase of HIF-1α expression by LPS under normoxic and hypoxic 
conditions reaching a peak at 4h, whilst hypoxia by itself did not affect mRNA level. 
Furthermore HIF-1α mRNA levels stimulated by LPS were decreased following Ado 
treatment both in normoxia and hypoxia, whilst Ado alone did not affect mRNA levels (Fig. 
21D). Finally, primary astrocytes were pre incubated for 4h under hypoxic conditions in the 
absence and in the presence of LPS and LPS plus Ado, followed by reoxygenation for up to 
30 min. Our results show that after the return of hypoxic astrocytes to normoxia, the levels of 
HIF-1α protein decreased very rapidly. In particular, LPS in the absence and in the presence 
of Ado did not alter the degradation rate of the HIF-1α protein, suggesting that a reduced or 
increased degradation of HIF-1 after reoxygenation was not affected by both LPS and Ado, 
respectively (Fig. 21E).  
Signalling pathways involved in the LPS-induced HIF-1α accumulation and effect of 
Ado 
To examine whether MAPK and Akt pathways were involved in the inhibitory effect 
mediated by Ado on LPS-induced HIF-1α accumulation, primary astrocytes were pretreated 
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with U0126 and SH5, inhibitors of MEK1/2, and Akt respectively, before exposure to LPS in 
normoxia and hypoxia. As shown in figure 22, U0126 and SH5 strongly reduced the LPS-
mediated HIF-1α stimulation, suggesting the involvement of ERK1/2 and Akt in this effect 
both in normoxia (A) and hypoxia (C). To confirm these data, phosphorylation of ERK and 
Akt was assessed following normoxia and hypoxia in the absence and in the presence of LPS, 
Ado and Ado with LPS. LPS increased ERK1/2 and Akt phosphorylation in normoxia (Fig. 
22B) and hypoxia (Fig. 22D) and Ado inhibited this effect under both conditions. 
Downstream HIF-1α target genes: effect of LPS and Ado 
Given the increase in the proportion of nuclear localized HIF-1α after treatment with LPS in 
both normoxia and hypoxia and the inhibitory effect of Ado, we then evaluated whether the 
transcriptional activity of HIF-1 was also affected in murine astrocytes. We looked for a 
series of genes that are known to be regulated by HIF-1, such as those for angiogenesis and 
cell metabolism. To this aim VEGF, GLUT1, GLUT3, HK2 and GAPDH were quantified 
under normoxic and hypoxic conditions. In normoxia, LPS did not modulate VEGF, GLUT3 
and GAPDH but increased GLUT1 (Fig. 23A) and HK2 (Fig.23C), in a time-dependent way. 
The involvement of HIF-1 in this effect was assessed by treating cells with echinomycin, an 
inhibitor which prevents HIF-1 binding to specific target promoter sequences. Furthermore, 
U0126 and SH5 were able to reduce the LPS mediated GLUT1 and HK2 increase, suggesting 
the involvement of ERK1/2 and Akt in this effect. Finally, CHA and Cl-IB-MECA inhibited 
LPS-induced mRNA increase of GLUT1 and HK2 and PSB36 and MRS 1523 reverted this 
effect (Fig. 23B and D, respectively). Hypoxia by itself induced an increase in VEGF, 
GLUT1, GLUT3, HK2, GAPDH mRNA expression in astrocytes; this effect was HIF-1 
dependent, because their level was reduced following incubation with HIF-1α siRNA and 
echinomycin, (Fig. 23 E-I). HIF-1α silencing for 72h reduced mRNA expression at 0.32±0.03 
in comparison to cells transfected with non-specific siRNActr (1.0±0.1) and also protein level 
was reduced (Suppl. Fig. 3). However LPS did not further increase the expression of VEGF, 
GLUT1, GLUT3, HK2, GAPDH in hypoxia, neither CHA and Cl-IB-MECA receptor 
agonists changed significantly the level of these genes (data not shown). Cell proliferation and 
survival were not affected by LPS and Ado at any time investigated (4,8,16h) (Suppl. Fig.4). 
Therefore we evaluated the regulation of genes involved in inflammation like iNOS and 
A2BARs. In normoxia iNOS levels were stimulated by LPS in a time-dependent way (Fig. 
24A). Hypoxia by itself induced a slight stimulation of iNOS, whilst the increase induced by 
LPS in concert with hypoxia was strong and time-dependent, starting from 4h and peaking at 
8h under hypoxia (Fig. 24B). The effect induced by LPS in normoxia was reduced by HIF-1α 
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inhibition, incubation with U0126 and SH5 suggesting that iNOS induction was stimulated by 
LPS through a pathway involving HIF-1α transcription factor, via ERK and Akt activation 
(Fig.24C). CHA and Cl-IB-MECA reduced iNOS mRNA level stimulated by LPS (Fig. 24C). 
Antagonism of PSB36 and MRS1523 reversed the CHA and Cl-IB-MECA reduction of iNOS 
mRNA level stimulated by LPS, confirming the involvement of A1 and A3 ARs in this 
response (Fig. 24C). The effect induced by hypoxia was HIF-1 dependent (Fig. 24D). 
Furthermore also the effect induced by LPS in hypoxia was reduced by HIF-1α silencing, 
incubation with echinomycin, U0126 and SH5 suggesting that iNOS induction was stimulated 
by LPS through a pathway involving HIF-1α transcription factor, via ERK and Akt activation 
(Fig. 24E). Like in normoxia A1 and A3 ARs inhibited this effect (Fig. 24F). Analogous 
results were obtained for A2BARs. In normoxia A2BARs were stimulated following LPS 
treatment. Hypoxia by itself increased A2BARs levels but LPS in concert with hypoxia 
induced a strong increase of A2B mRNA values (Fig. 25A). The increase was reduced 
following echinomycin, U0126 and SH5 treatment (Fig. 25B) suggesting again a role for HIF-
1α, via ERK and Akt activation in the LPS increase. The LPS stimulatory effect on A2B 
expression was reduced by CHA and Cl-IB-MECA and restored in the presence of PSB36 and 
MRS 1523 receptor antagonists (Fig. 25B). The increase induced by hypoxia alone was HIF-1 
dependent (Fig. 25C). Furthermore also the effect induced by LPS in hypoxia, on A2BAR 
levels involved the activation of HIF-1α transcription factor, via ERK and Akt pathways (Fig. 
25D). Like in normoxia A1 and A3 ARs inhibited this effect (Fig. 25E).  
Ado-mediated inhibition of LPS-stimulated iNOS and A2B AR expression 
We investigated the stimulatory effect induced by LPS on iNOS and A2BARs protein level 
and the inhibition exerted by Ado in primary astrocytes. As shown in figure 26A iNOS was 
not detectable in both normoxia and hypoxia without LPS stimulation and was increased 
following LPS treatment. The effect of LPS was higher when cells were incubated in hypoxia, 
and Ado was able to strongly reduce iNOS protein level stimulated by LPS under both 
normoxia and hypoxia. Accordingly, when nitrite levels were evaluated in the supernatant of 
murine astrocytes an increase following LPS incubation and a reduction in cells treated with 
Ado was observed in both conditions (Fig. 26B). Similarly a significant increase in A2BAR 
protein levels following LPS incubation under normoxic and hypoxic conditions was 
observed. The effect of LPS was higher in cells incubated in hypoxia and a reduction of this 
effect in Ado treated cells was detected according to mRNA data (Fig. 26C). The specificity 
of the bands is demonstrated by their reduction after treatment of primary astrocytes for 48-72 
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h with siRNA of A2BAR in comparison to control cells transfected with non-specific random 
control ribonucleotides (Suppl. Fig. 5).  
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Discussion 
 
HIF-1α is an important protein in the regulation/induction of many genes in the cellular 
response to hypoxia and a central mediator in inflammatory signalling. In this study, we have 
provided evidence, for the first time, that Ado is able to decrease HIF-1α expression and 
protein  accumulation induced by LPS in murine astrocytes under both normoxic and hypoxic 
conditions. By using agonists, antagonists and receptor silencing, we found that A1 and A3 
ARs were responsible for the Ado-mediated inhibitory effect. The inhibitory effect of Ado on 
HIF-1α levels was quite surprising, as the nucleoside usually increased HIF-1α levels in 
peripheral cells, by activating different receptor subtypes, depending on the cellular model 
investigated. A2AARs have been linked to HIF-1α accumulation in human and murine 
macrophages (De Ponti et al., 2007; Ramanathan et al., 2007; Ernens et al., 2010), A3, A2B 
ARs in tumor cells and in foam cells (Merighi et al., 2005; Gessi et al., 2008; 2010),  A1 ARs 
in neonatal rats and mesenchymal cells (Gessi et al., 2012; Wendler et al., 2007). In general, 
the role of HIF-1 in astrocytes has received much less attention in comparison to neurons, 
although astrocytes also play critical roles in health and disease. In particular, astrocytes and 
Ado have a clear role in mediating the protective effects on neurons (Vangeinson and Rempe, 
2009). In this regard, selective loss of HIF-1 in astrocytes profoundly inhibits hypoxia-
induced neuronal death, whereas loss of HIF-1 function in neurons increased neuronal 
susceptibility to hypoxia induced damage, suggesting that the adaptive and pathological 
function of HIF-1 is cell type specific (Vangeinson et al., 2008). So the inhibition of HIF-1 
stimulated by LPS in both normoxia and hypoxia may be considered another neuroprotective 
mechanism operated by Ado against brain injuries. Our data show also, for the first time, that 
LPS stimulates HIF-1α accumulation in murine astrocytes, through an increase in mRNA 
expression, in both normoxic and hypoxic conditions. Accordingly, it is known that HIF-1α 
transcription is detected as an essential mechanism of HIF-1α activation in response to 
bacterial infection and has been observed previously in human macrophages and in other glial 
cells (Nizet and Johnson, 2009; Frede et al., 2006; Oh et al., 2008; Yao et al., 2008; 2013). 
Downstream signaling of LPS leads to the activation of a wide variety of signalling pathway, 
including activation of the p44/42 MAPK cascade. We observed a significant increase in 
p44/42 phopshorylation after LPS treatment under normoxia and hypoxia, which was 
followed by HIF-1α protein accumulation. Activation of p44/42 MAPK seems to be critical 
for LPS-induced HIF-1α accumulation and for the inhibitory effect exerted by Ado, since 
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inhibition of the upstream kinase MEK1/2 by U0126 reduced HIF-1α accumulation induced 
by LPS and Ado inhibited LPS-stimulated ERK phosphorylation. Accordingly, previous 
results show that LPS increased HIF-1α mRNA expression by activating upstream p44/42 
MAPK in human monocytes (Frede et al., 2006). As for the effect of ARs on this pathway, 
Cl-IB-MECA has been reported to reduce p44/42 MAPK phosphorylation in melanoma cells 
(Merighi et al., 2005a) and to induce a biphasic effect on ERK1/2 phosphorylation in 
microglia cells (Hammarberg et al., 2003). Usually all ARs activate the ERK1/2 pathway in 
CHO cells, anyway nothing is known about ARs signalling in glial cells stimulated by LPS 
(Schulte and Fredholm, 2002). Another pathway linked to HIF- 1α accumulation is PI3K/Akt 
(Semenza, 2002). In our system, LPS-induced HIF-1α accumulation was inhibited by SH5 
and accordingly an increase in Akt phosphorylation following LPS stimulation was observed. 
Ado decreased this effect as previously observed in microglial cells where Cl-IB-MECA, 
through inhibition of Akt pathway, inhibited pro-inflammatory cytokine expression (Lee et 
al., 2006). A wide variety of genes that regulate major cellular processes, like glicolysis, 
angiogenesis and inflammation are activated by HIF-1; some of them are known to be 
regulated by LPS and Ado as well. In normoxic astrocytes LPS did not affect VEGF, GLUT3 
and GAPDH expression whilst, through HIF-1 activation, induced an increase in glucose 
transporter isoform GLUT1 and glycolysis-associated enzyme HK2. Stimulation of A1, A3 
ARs reduced this effect, possibly to limit glucose consumption by astrocytes during 
inflammation. In hypoxic astrocytes we found that VEGF, GLUT-1, GLUT-3, HK-2, GAPDH 
were upregulated by hypoxia in an HIF-1 dependent way, but they were not further increased 
by LPS, suggesting that the amount of HIF-1 induced by hypoxia alone is probably sufficient 
to induce these genes very efficiently as already observed by Jantsch and coworkers in 
myeloid cells (Jantsch et al., 2011). In contrast, as for genes involved in inflammation we 
found that LPS increased iNOS levels in normoxia, hypoxia by itself had only minor effects 
on iNOS expression and LPS in concert with hypoxia markedly increased iNOS level, 
suggesting that hypoxia and HIF-1 are insufficient for a robust induction of iNOS mRNA and 
protein. Accordingly we did not detect iNOS protein under hypoxia alone, suggesting that 
iNOS is a TLR-induced, inflammatory HIF-1α-dependent gene (Jantsch et al., 2011). Whilst 
glial activation and iNOS expression alone do not always lead to neuronal death, extensive 
damage has been demonstrated if inflammatory activation of astrocytes was combined with 
hypoxia (Mander et al., 2005). NO has been implicated in DNA damage, PARP activation and 
induction of apoptosis (Vangeinson and Rempe, 2009). The results of this study reveal that A1 
and A3 activation inhibited iNOS induction in astrocytes in both normoxic and hypoxic 
conditions supporting a protective effect during inflammation and hypoxic injury. 
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Accordingly, protection from hypoxic damage and reduction of apoptosis by A1 and A3 
subtypes has been suggested also by Fredholm’s group in primary astrocytes (Björklund et al., 
2008). Furthermore an inhibitory effect on iNOS induction has been already observed 
following A1 and A3 activation in PC12 and macrophages, respectively supporting their anti-
inflammatory role (Pingle et al., 2007; Fishman et al., 2012; Lee et al., 2011). It is well known 
that hypoxia induces an increase in Ado providing an endogenous signal that dampens 
excessive inflammation and promotes tissue repair and healing  (Poth et al., 2013; Haskò et 
al., 2008). Several studies have suggested that signaling through A2BARs may be involved in 
tissue protection during hypoxia (Poth et al., 2013). The A2BAR has been demonstrated to 
play a role in both stimulation or inhibition of cytokine release, which can exacerbate or 
reduce inflammation (Zhong et al., 2004; Vazquéz et al., 2008; Koscsò et al., 2012; Thimm et 
al., 2013). In astroglial cells, a bi-directional relation between cytokines and A2BARs has been 
reported as an important mechanism to modulate the cerebral damage progression (Fredholm 
and Altiok, 1994). Its expression is decreased by proinflammatory cytokines following acute 
treatment but is upregulated after chronic cytokines exposure resulting in excessive astrocytic 
activation (Trincavelli et al., 2004; 2008). We found that A2BAR level was stimulated 
following LPS activation, raised by hypoxia alone and further increased after LPS stimulation 
in concert with hypoxia in an HIF-1 dependent way; the HIF-1 dependent modulation of 
A2BAR in hypoxia was according to previous studies (Poth et al., 2013). The increase induced 
by LPS both in normoxia and hypoxia was reduced by A1 and A3 ARs activation, suggesting a 
potential mechanism to dampen excessive activation(Gessi et al, 2013).   
In summary, our results show for the first time that Ado, through A1 and A3 ARs activation, 
reduces LPS-stimulated HIF-1α mRNA expression and protein accumulation by inhibiting 
LPS triggered p44/42 MAPK and Akt phosphorylation in normoxic and hypoxic conditions. 
This leads to an inhibition of genes involved in inflammation like iNOS and A2BARs, that are 
stimulated by LPS and further increased by LPS in concert with hypoxia, whilst does not 
affect angiogenesis and metabolic related genes, with the exception of GLUT1 and HK2 that 
are stimulated by LPS in normoxia and reduced by A1 and A3 ARs activation. These findings 
add a new molecular pathway activated by Ado in astrocytes to give a reduction of genes 
involved in inflammation and hypoxic injury that may cohexist in stroke, ischemia and other 
CNS disorders.  
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Figures Legend 
 
Figure 16: Murine astrocytes accumulate HIF-1 in response to LPS stimulation. (A and B) 
Astrocytes were incubated under normoxic (A) and hypoxic (B) conditions for up to 8 h in the 
presence or absence of LPS (1µg/ml). (C and D) Astrocytes were incubated for 4 h in 
normoxic (C) and hypoxic (D) conditions in the presence of increasing concentrations of LPS 
(0.01, 0.1, 1 µg/ml). HIF-1and actin were detected by immunoblotting in whole cell lysates. 
Actin shows equal loading protein. Densitometric quantification of HIF-1 Western blots is the 
mean ± SE values (N = 4); cells in the absence of LPS (A and C) and cells in the absence of 
LPS incubated for 4 h in hypoxia (B and D) were set to 100%(Control). *P < 0.05 compared 
with cells in the absence of LPS.
§
P < 0.05 compared with cells in the absence of LPS at each 
time of hypoxia. 
#
P < 0.05 compared with cells in the absence of LPS incubated for 4 h in 
hypoxia. 
Figure 17: Ado, A1 and A3 ARs agonists inhibit HIF-1 accumulation stimulated by LPS. (A 
and D) Cells were pretreated for 30 min with increasing concentrations (1,10, 100 µM) of 
Ado; (B and E) (1, 10, 100 nM) CHA; (C and F) (1, 10, 100 nM) Cl-IB-MECA, before 
stimulation with LPS (1 µg/ml) for 4 h in normoxia (A–C) and hypoxia (D–F). The protein 
levels of HIF-1were determined by Western blotting in whole cell lysates and actin served as 
control for equal protein loading. Densitometric quantification of HIF-1Western blots is the 
mean ± SE values (N = 4); cells in the absence of LPS was set to 100% in A and D; cells in 
the presence of LPS without agonists was set to 100% in B, C, E and F; *P < 0.05,
§
P < 0.05 
compared with cells treated with LPS in the absence of Ado or receptor agonists in normoxia 
and hypoxia, respectively. 
Figure 18: Ado inhibits HIF-1 nuclear localization induced by LPS stimulation inmurine 
astrocytes in normoxia. (A–F) Cells were incubated under normoxia (4 h) in the presence of 
LPS stimulation (C–F) and Ado 100 µM (E and F). HIF-1nuclear accumulation was evaluated 
by means of immunofluorescence analysis; (G) bargraph data expressed as mean ± SE 
percentage of HIF-1staining (N = 4 for each group); *P < 0.05 vs cells in the presence of LPS. 
(B, D and F) The fluorescent dye DAPI was used to stain the nuclei of all astrocytes. Figure 
shows 1 representative experiment. 
Figure 19: Ado inhibits HIF-1 nuclear localization induced by LPS stimulation in murine 
astrocytes in hypoxia. (A–F) Cells were incubated under hypoxia (4 h) in the presence of LPS 
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stimulation (C–F) and Ado 100 µM (E and F). HIF-1nuclear accumulation was evaluated by 
means of immunofluorescence analysis; (G) bargraph data expressed as mean ± SE 
percentage of HIF-1staining (N = 4 for each group);
§
P < 0.05 vs cells in the presence of LPS 
in hypoxia. (B, D and F) The fluorescent dye DAPI was used to stain the nuclei of all 
astrocytes. Figure shows 1 representative experiment. 
Figure 20: Effect of A1and A3 ARs antagonists and receptor silencing on HIF-1 protein 
increase stimulated by LPS. (A and B) Effect of CHA (30 nM) and Cl-IB-MECA (100 nM), 
on HIF-1 protein accumulation induced by LPS under normoxia (A) and hypoxia (4 h) (B) 
and antagonism by 10 nM PSB 36 and 1 µM MRS 1523. The protein levels of HIF-1were 
determined by Western blotting in nuclear extracts and actin served as control for equal 
protein loading. Densitometric quantification of Western blots is the mean ± SE values (N = 
4); 
*
P < 0.05,
§
P < 0.05 compared with LPS in normoxia and hypoxia, respectively. (C and D) 
Ado effect on HIF-1 levels stimulated by LPS under hypoxia in the presence of siRNA of 
A1(C) and A3(D) ARs (lines 4–6) or siRNActr (lines 1–3). The protein levels of HIF-1were 
determined by Western blotting in nuclear extracts and actin served as control for equal 
protein loading. Densitometric quantification of Western blots is the mean ± SE values (N = 
4);
§
P < 0.05 compared with LPS in hypoxia;
#
P < 0.05 compared with cells treated with Ado + 
LPS in hypoxia. Cells in the absence of LPS were set to 100% (control). 
Figure 21: Molecular mechanism involved in the inhibitory effect mediated by Ado on LPS-
induced HIF-1 accumulation. (A and B) Cells were treated with ActD (10 mg/ml) before a 4 h 
incubation with LPS under normoxic (A) and hypoxic (B) conditions. HIF-1 and actin were 
detected by immunoblotting in whole cell lysates. Densitometric quantification of HIF-1 
Western blots is the mean ± SE values (N = 4); (C) total RNA was extracted from cells treated 
in normoxia (white bars) and in hypoxia (black bars)without and with LPS for 2, 4 and 8 h. 
Data were expressed as fold of increase vs control arbitrarily fixed as 1 (cells in the absence 
of LPS in normoxia). *P < 0.05 compared with control in normoxia. (D) Total RNA was 
extracted from cells pretreated with 100 µM Ado before addition of LPS for 4 h in normoxia 
(white bars) and hypoxia (black bars). Data were expressed as fold of increase vs control 
arbitrarily fixed as 1 (cells in the absence of LPS). *P < 0.05,
§
P < 0.05 compared with cells in 
the absence of LPS in normoxia and hypoxia, respectively. (E) Astrocytes were incubated 
under hypoxic conditions in the absence or presence of LPS and LPS + Ado. After 4 h, cells 
were exposed to normoxia and a time course of HIF-1 disappearance was performed at 0, 5, 
10 and 15 min. The mean densitometry data from four independent experiments were 
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normalized to the result obtained at time 0 (control). The fraction (%) of remaining HIF-1 is 
indicated. 
Figure 22: Signaling pathways involved in the inhibitory effect mediated by Ado on LPS-
induced HIF-1 accumulation. (A and C) Cells were preincubated with the MEK1/2 inhibitor 
U0126 10µM and the Akt blocker SH5 10µM before addition of LPS in normoxia and 
hypoxia (4 h), respectively. HIF-1and actin were detected by immunoblotting in whole cell 
lysates. Actin shows equal loading protein. Densitometric quantification of HIF-1 Western 
blots is the mean ± SE values (N = 4); cells in the absence of LPS were set to 100%. (B and 
D) Astrocytes were treated without and with LPS, Ado and Ado + LPS under normoxia and 
hypoxia (15 min), respectively. Phosphorylated p44/42MAPK, pAkt as well as total MAPK 
and Akt, were detected by immunoblot. Densitometric quantification of p44/42 MAPK, pAkt 
Western blots is the mean ± SE values (N = 4).     *P < 0.05,
§
P < 0.05 compared with cells in 
the presence of LPS in normoxia and hypoxia, respectively. 
Figure 23: Downstream HIF-1 target genes involved in cell metabolism and angiogenesis in 
normoxia and hypoxia. (A and C) Cells were incubated in the presence of LPS under 
normoxia for 4, 8 and 16 h and mRNA levels of GLUT-1 (A) and HK2 (C), were evaluated 
by real-time RT-PCR. (B and D) Cells were incubated with LPS in normoxia after 
pretreatment with 20 nM echinomycin, 10 µM U0126, 10 µM SH5, 30 nM CHA, 100 nM Cl-
IB-MECA, 10 nM PSB36 and 1 µM MRS 1523 and mRNA levels of GLUT-1 (B) and HK2 
(D) were evaluated. Data were expressed as fold of increase vs control (cells without LPS), 
arbitrarily fixed as 1. *P < 0.05 compared with cells without LPS; 
#
P < 0.05 compared with 
cells with LPS. (E-I) Cells were incubated in normoxia and hypoxia for 8 h in the absence and 
in the presence of siRNActr, siRNA-HIF-1, 20 nM echinomycin and mRNA levels of VEGF, 
GLUT-1, GLUT-3, HK2 and GAPDH, were evaluated by real-time RT-PCR. Data of hypoxia 
were expressed as fold of increase vs normoxia, arbitrarily fixed as 1; data of HIF-1siRNA 
and echinomycin were expressed as fold of increase vs hypoxia. 
§
P < 0.05 compared with 
cells in hypoxia. 
Figure 24: iNOS is stimulated by LPS in normoxia and hypoxia through a pathway involving 
HIF, ERK1/2 and Akt and A1, A3 ARs inhibit this effect. (A and B) Cells were incubated with 
LPS in normoxia and hypoxia for 4, 8 and 16 h and mRNA levels of iNOS were evaluated by 
real-time RT-PCR. Data were expressed as fold of increase vs normoxia, arbitrarily fixed as 
1. (C–F) Astrocytes were incubated with LPS in the absence and in the presence of 
echinomycin, U0126, SH5, CHA, Cl-IB-MECA, PSB36 and MRS1523 in normoxia (C) and 
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hypoxia (D–F) and mRNA levels of iNOS were evaluated. Data were expressed as fold of 
increase vs control (cells in the absence of LPS), arbitrarily fixed as 1. In (D) data of hypoxia 
were expressed as fold of increase vs normoxia, arbitrarily fixed as 1; data of  HIF-1siRNA 
and echinomycin were expressed as fold of increasevs hypoxia. *P < 0.05 compared with 
cells in normoxia,
#
P < 0.05 compared with cells treated with LPS in normoxia,
§
P < 0.05 
compared with cells exposed to hypoxia and 
†
P < 0.05 compared with cells exposed to LPS 
and hypoxia. Mean ± SE values from four experiments are shown. 
Figure 25: A2BAR is stimulated by LPS in normoxia and hypoxia through a pathway 
involving HIF, ERK1/2 and Akt and A1, A3 ARs inhibit this effect. (A) Cells were incubated 
with LPS in normoxia and hypoxia for 4, 8 and 16 h and mRNA levels of A2B were evaluated 
by real-time RT-PCR. Data were expressed as fold of increase vs normoxia, arbitrarily fixed 
as 1. (B–E) Astrocytes were incubated with LPS in the absence and in the presence of 
echinomycin, U0126, SH5, CHA, Cl-IB-MECA, PSB36 and MRS1523 in normoxia (B) and 
hypoxia (C–E) and mRNA levels of A2B were evaluated. Data were expressed as fold of 
increase vs control (cells in the absence of LPS), arbitrarily fixed as 1. In (C) data of hypoxia 
were expressed as fold of increase vs normoxia, arbitrarily fixed as 1; data of HIF-1siRNA 
and echinomycin were expressed as fold of increase vs hypoxia. *P < 0.05 compared with 
cells in normoxia, 
#
P < 0.05 compared with cells treated with LPS in normoxia, 
§
P < 0.05 
compared with cells exposed to hypoxia and 
†
P < 0.05 compared with cells exposed to LPS 
and hypoxia. Mean ± SE values from four experiments are shown. 
Figure 26: Inhibition by Ado on LPS-stimulated iNOS and A2B protein levels in normoxia 
and hypoxia. (A and C) Astrocytes were treated with 100 µM Ado before addition of LPS 
under normoxia and hypoxia. Protein levels of iNOS (A) and A2B(C) were evaluated by 
means of Western blotting in whole cell lysates, actin shows equal loading protein. 
Densitometric quantification of  iNOS and A2B Western blots is the mean ± SE values (N = 
4). (B) Astrocytes were treated with 100 µM Ado before addition of LPS under normoxia and 
hypoxia and nitrite levels were evaluated by Greiss reaction. Bar graph of colorimetric nitrite 
assay is the mean ± SE values (N = 4). *P < 0.05, 
§
P < 0.05 compared with cells in the 
presence of LPS in normoxia and hypoxia, respectively. 
Supplemental Figure 2: Western blot analysis using anti A1 and A3 ARs polyclonal 
antibodies of protein extracts from cells treated with siRNA-A1 and siRNA-A3 and cultured 
for 24, 48 and 72 h; cells transfected with siRNActr for 72 h (line 1). Actin shows equal 
loading protein. *P < 0.05 vs cells transfected with siRNActr for 72 h. 
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Supplemental Figure 3: Western blot analysis using anti HIF-1 receptor polyclonal antibody 
of protein extracts from cells treated with siRNA-HIF-1 and cultured for 24, 48 and 72 h; 
cells transfected with siRNActr for 72 h (line 1). Actin shows equal loading protein. *P < 0.05 
vs cells transfected with siRNActr for 72 h. 
Supplemental Figure 4: MTS assay. Cell growth is expressed as a percentage of the OD 
measured in untreated cells (control) assumed as 100% of cell viability. Ordinate reports 
means of OD quantifications ± SEM (N = 4). 
Supplemental Figure 5: Western blot analysis using anti A2BAR polyclonal antibodies of 
protein extracts from cells treated with siRNA-A2B and cultured for 24, 48 and 72 h; cells 
transfected with siRNActr for 72 h (line 1). Actin shows equal loading protein. *P < 0.05 vs 
cells transfected with siRNActr for 72 h. 
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